<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><front><journal-meta><journal-id journal-id-type="nlm-ta">Nutrients</journal-id><journal-id journal-id-type="iso-abbrev">Nutrients</journal-id><journal-id journal-id-type="publisher-id">nutrients</journal-id><journal-title-group><journal-title>Nutrients</journal-title></journal-title-group><issn pub-type="epub">2072-6643</issn><publisher><publisher-name>MDPI</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">28346333</article-id><article-id pub-id-type="pmc">5409664</article-id><article-id pub-id-type="doi">10.3390/nu9040325</article-id><article-id pub-id-type="publisher-id">nutrients-09-00325</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Clinical Benefits of <italic>n</italic>-3 PUFA and ɤ-Linolenic Acid in Patients with Rheumatoid Arthritis</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Veselinovic</surname><given-names>Mirjana</given-names></name><xref ref-type="aff" rid="af1-nutrients-09-00325">1</xref></contrib><contrib contrib-type="author"><name><surname>Vasiljevic</surname><given-names>Dragan</given-names></name><xref ref-type="aff" rid="af2-nutrients-09-00325">2</xref></contrib><contrib contrib-type="author"><name><surname>Vucic</surname><given-names>Vesna</given-names></name><xref ref-type="aff" rid="af3-nutrients-09-00325">3</xref></contrib><contrib contrib-type="author"><name><surname>Arsic</surname><given-names>Aleksandra</given-names></name><xref ref-type="aff" rid="af3-nutrients-09-00325">3</xref></contrib><contrib contrib-type="author"><name><surname>Petrovic</surname><given-names>Snjezana</given-names></name><xref ref-type="aff" rid="af3-nutrients-09-00325">3</xref></contrib><contrib contrib-type="author"><name><surname>Tomic-Lucic</surname><given-names>Aleksandra</given-names></name><xref ref-type="aff" rid="af1-nutrients-09-00325">1</xref></contrib><contrib contrib-type="author"><name><surname>Savic</surname><given-names>Maja</given-names></name><xref ref-type="aff" rid="af4-nutrients-09-00325">4</xref></contrib><contrib contrib-type="author"><name><surname>Zivanovic</surname><given-names>Sandra</given-names></name><xref ref-type="aff" rid="af5-nutrients-09-00325">5</xref></contrib><contrib contrib-type="author"><name><surname>Stojic</surname><given-names>Vladislava</given-names></name><xref ref-type="aff" rid="af6-nutrients-09-00325">6</xref></contrib><contrib contrib-type="author"><name><surname>Jakovljevic</surname><given-names>Vladimir</given-names></name><xref ref-type="aff" rid="af7-nutrients-09-00325">7</xref><xref rid="c1-nutrients-09-00325" ref-type="corresp">*</xref></contrib></contrib-group><aff id="af1-nutrients-09-00325"><label>1</label>Department of Internal medicine, Faculty of Medical Sciences, University of Kragujevac, Kragujevac 34000, Serbia; <email>veselinovic.m@sbb.rs</email> (M.V.); <email>sanlusa@ptt.rs</email> (A.T.-L.)</aff><aff id="af2-nutrients-09-00325"><label>2</label>Department of Hygiene, Institute for Public Health, Faculty of Medical Sciences, University of Kragujevac, Kragujevac 34000, Serbia; <email>dvg_gana@yahoo.com</email></aff><aff id="af3-nutrients-09-00325"><label>3</label>Centre of Research Excellence in Nutrition and Metabolism, Institute for Medical Research, University of Belgrade, Beograd 11000, Serbia; <email>vesna.vucic.imr@gmail.com</email> (V.V.); <email>vesna.vucic.imr@gmail.com</email> (A.A.); <email>snjezana570.imr12@gmail.com</email> (S.P.)</aff><aff id="af4-nutrients-09-00325"><label>4</label>Department of Pharmacy, Faculty of Medical Sciences, University of Kragujevac, Kragujevac 34000, Serbia; <email>maja.jovanovic.2008.38@gmail.com</email></aff><aff id="af5-nutrients-09-00325"><label>5</label>Faculty of Hotel Management and Tourism, Department of Natural Sciences and medicine, University of Kragujevac, Kragujevac 34000, Serbia; <email>zivanovicsandra@hotmail.com</email></aff><aff id="af6-nutrients-09-00325"><label>6</label>Faculty of Medical Sciences, University of Kragujevac, Kragujevac 34000, Serbia; <email>vladisavastojic@medf.kg.ac.rs</email></aff><aff id="af7-nutrients-09-00325"><label>7</label>Faculty of Medical Sciences, University of Kragujevac, Physiology, Kragujevac 34000, Serbia</aff><author-notes><corresp id="c1-nutrients-09-00325"><label>*</label>Correspondence: <email>drvladakgbg@yahoo.com</email></corresp></author-notes><pub-date pub-type="epub"><day>25</day><month>3</month><year>2017</year></pub-date><pub-date pub-type="collection"><month>4</month><year>2017</year></pub-date><volume>9</volume><issue>4</issue><elocation-id>325</elocation-id><history><date date-type="received"><day>28</day><month>11</month><year>2016</year></date><date date-type="accepted"><day>08</day><month>3</month><year>2017</year></date></history><permissions><copyright-statement>© 2017 by the authors.</copyright-statement><copyright-year>2017</copyright-year><license license-type="open-access"><license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><abstract><p><offsets xml_i="5542" xml_f="5565" txt_i="11" txt_f="34">(1) Background: Marine </offsets><italic><offsets xml_i="5573" xml_f="5574" txt_i="34" txt_f="35">n</offsets></italic><offsets xml_i="5583" xml_f="6337" txt_i="35" txt_f="789">-3 polyunsaturated fatty acids (PUFA) and ɤ-linolenic acid (GLA) are well-known anti-inflammatory agents that may help in the treatment of inflammatory disorders. Their effects were examined in patients with rheumatoid arthritis; (2) Methods: Sixty patients with active rheumatoid arthritis were involved in a prospective, randomized trial of a 12 week supplementation with fish oil (group I), fish oil with primrose evening oil (group II), or with no supplementation (group III). Clinical and laboratory evaluations were done at the beginning and at the end of the study; (3) Results: The Disease Activity Score 28 (DAS 28 score), number of tender joints and visual analogue scale (VAS) score decreased notably after supplementation in groups I and II (</offsets><italic><offsets xml_i="6345" xml_f="6346" txt_i="789" txt_f="790">p</offsets></italic><offsets xml_i="6355" xml_f="6397" txt_i="790" txt_f="829"> &lt; 0.001). In plasma phospholipids the </offsets><italic><offsets xml_i="6405" xml_f="6406" txt_i="829" txt_f="830">n</offsets></italic><offsets xml_i="6415" xml_f="6418" txt_i="830" txt_f="833">-6/</offsets><italic><offsets xml_i="6426" xml_f="6427" txt_i="833" txt_f="834">n</offsets></italic><offsets xml_i="6436" xml_f="6501" txt_i="834" txt_f="899">-3 fatty acids ratio declined from 15.47 ± 5.51 to 10.62 ± 5.07 (</offsets><italic><offsets xml_i="6509" xml_f="6510" txt_i="899" txt_f="900">p</offsets></italic><offsets xml_i="6519" xml_f="6569" txt_i="900" txt_f="950"> = 0.005), and from 18.15 ± 5.04 to 13.50 ± 4.81 (</offsets><italic><offsets xml_i="6577" xml_f="6578" txt_i="950" txt_f="951">p</offsets></italic><offsets xml_i="6587" xml_f="6649" txt_i="951" txt_f="1013"> = 0.005) in groups I and II respectively. The combination of </offsets><italic><offsets xml_i="6657" xml_f="6658" txt_i="1013" txt_f="1014">n</offsets></italic><offsets xml_i="6667" xml_f="6750" txt_i="1014" txt_f="1097">-3 PUFA and GLA (group II) increased ɤ-linolenic acid (0.00 ± 0.00 to 0.13 ± 0.11, </offsets><italic><offsets xml_i="6758" xml_f="6759" txt_i="1097" txt_f="1098">p</offsets></italic><offsets xml_i="6768" xml_f="6885" txt_i="1098" txt_f="1212"> &lt; 0.001), which was undetectable in all groups before the treatments; (4) Conclusion: Daily supplementation with </offsets><italic><offsets xml_i="6893" xml_f="6894" txt_i="1212" txt_f="1213">n</offsets></italic><offsets xml_i="6903" xml_f="7029" txt_i="1213" txt_f="1339">-3 fatty acids alone or in combination with GLA exerted significant clinical benefits and certain changes in disease activity.</offsets></p></abstract><kwd-group><kwd><italic>n</italic>-3 PUFA</kwd><kwd>ɤ-linolenic acid</kwd><kwd>rheumatoid arthritis</kwd></kwd-group></article-meta></front><body><sec id="sec1-nutrients-09-00325"><title><offsets xml_i="7231" xml_f="7246" txt_i="1347" txt_f="1362">1. Introduction</offsets></title><p><offsets xml_i="7257" xml_f="7585" txt_i="1363" txt_f="1691">Rheumatoid arthritis (RA) is one of the most common autoimmune disorders. The main characteristic of RA is the onset of pathological changes in the lining of the joints. Due to the infiltration of macrophages, B cells, and CD4+ helper T cells into the synovial stroma, synovium proliferates causing swelling and pain of joints [</offsets><xref rid="B1-nutrients-09-00325" ref-type="bibr"><offsets xml_i="7635" xml_f="7636" txt_i="1691" txt_f="1692">1</offsets></xref><offsets xml_i="7643" xml_f="7644" txt_i="1692" txt_f="1693">,</offsets><xref rid="B2-nutrients-09-00325" ref-type="bibr"><offsets xml_i="7694" xml_f="7695" txt_i="1693" txt_f="1694">2</offsets></xref><offsets xml_i="7702" xml_f="7883" txt_i="1694" txt_f="1875">]. Furthermore, the overproduction of inflammatory molecules, prostaglandin E2 (PGE2), tumour necrosis factor (TNF), interleukin (IL)-1, and cytokines induces chronic inflammation [</offsets><xref rid="B3-nutrients-09-00325" ref-type="bibr"><offsets xml_i="7933" xml_f="7934" txt_i="1875" txt_f="1876">3</offsets></xref><offsets xml_i="7941" xml_f="7942" txt_i="1876" txt_f="1877">,</offsets><xref rid="B4-nutrients-09-00325" ref-type="bibr"><offsets xml_i="7992" xml_f="7993" txt_i="1877" txt_f="1878">4</offsets></xref><offsets xml_i="8000" xml_f="8183" txt_i="1878" txt_f="2061">]. Especially IL-1 and TNF play important roles in inflammation during RA. Numerous randomized controlled clinical trials have reported a strong anti-inflammatory potential of marine </offsets><italic><offsets xml_i="8191" xml_f="8192" txt_i="2061" txt_f="2062">n</offsets></italic><offsets xml_i="8201" xml_f="8244" txt_i="2062" txt_f="2105">-3 long-chain polyunsaturated fatty acids (</offsets><italic><offsets xml_i="8252" xml_f="8253" txt_i="2105" txt_f="2106">n</offsets></italic><offsets xml_i="8262" xml_f="8315" txt_i="2106" txt_f="2159">-3 LC-PUFAs) and improved clinical parameters of RA [</offsets><xref rid="B5-nutrients-09-00325" ref-type="bibr"><offsets xml_i="8365" xml_f="8366" txt_i="2159" txt_f="2160">5</offsets></xref><offsets xml_i="8373" xml_f="8374" txt_i="2160" txt_f="2161">,</offsets><xref rid="B6-nutrients-09-00325" ref-type="bibr"><offsets xml_i="8424" xml_f="8425" txt_i="2161" txt_f="2162">6</offsets></xref><offsets xml_i="8432" xml_f="8508" txt_i="2162" txt_f="2238">]. These effects are mostly attributed to eicosapentaenoic acid (EPA, C20:5 </offsets><italic><offsets xml_i="8516" xml_f="8517" txt_i="2238" txt_f="2239">n</offsets></italic><offsets xml_i="8526" xml_f="8567" txt_i="2239" txt_f="2280">-3) and docosahexaenoic acid (DHA, C22:6 </offsets><italic><offsets xml_i="8575" xml_f="8576" txt_i="2280" txt_f="2281">n</offsets></italic><offsets xml_i="8585" xml_f="8694" txt_i="2281" txt_f="2390">-3) acting in two ways. Firstly, they interfere with the enzymatic conversion of arachidonic acid (AA, C20:4 </offsets><italic><offsets xml_i="8702" xml_f="8703" txt_i="2390" txt_f="2391">n</offsets></italic><offsets xml_i="8712" xml_f="8905" txt_i="2391" txt_f="2584">-6) to pro–inflammatory prostaglandins (PGs) and leukotrienes (LTs). Secondly, EPA is a direct precursor in biosynthetic pathway of anti-inflammatory PGs (series-3) and LTs (series-5). Dietary </offsets><italic><offsets xml_i="8913" xml_f="8914" txt_i="2584" txt_f="2585">n</offsets></italic><offsets xml_i="8923" xml_f="9129" txt_i="2585" txt_f="2791">-3 LC-PUFAs replace AA in the phospholipid bilayer of the cell and then alter the membrane composition and fluidity, as well as cell signalling, gene transcription and metabolism of proresolving mediators [</offsets><xref rid="B7-nutrients-09-00325" ref-type="bibr"><offsets xml_i="9179" xml_f="9180" txt_i="2791" txt_f="2792">7</offsets></xref><offsets xml_i="9187" xml_f="9188" txt_i="2792" txt_f="2793">,</offsets><xref rid="B8-nutrients-09-00325" ref-type="bibr"><offsets xml_i="9238" xml_f="9239" txt_i="2793" txt_f="2794">8</offsets></xref><offsets xml_i="9246" xml_f="9247" txt_i="2794" txt_f="2795">,</offsets><xref rid="B9-nutrients-09-00325" ref-type="bibr"><offsets xml_i="9297" xml_f="9298" txt_i="2795" txt_f="2796">9</offsets></xref><offsets xml_i="9305" xml_f="9306" txt_i="2796" txt_f="2797">,</offsets><xref rid="B10-nutrients-09-00325" ref-type="bibr"><offsets xml_i="9357" xml_f="9359" txt_i="2797" txt_f="2799">10</offsets></xref><offsets xml_i="9366" xml_f="9776" txt_i="2799" txt_f="3209">]. Specialized proresolving mediators (resolvins, protectins and maresins) are bioactive lipid regulators implicated in the termination of inflammation by acting through specific G protein-coupled receptors. The resolution of inflammation is mediated by the termination of neutrophil recruitment, stimulation of apoptotic cells phagocytosis by macrophages, and their subsequent leaving of inflammatory tissue [</offsets><xref rid="B11-nutrients-09-00325" ref-type="bibr"><offsets xml_i="9827" xml_f="9829" txt_i="3209" txt_f="3211">11</offsets></xref><offsets xml_i="9836" xml_f="9837" txt_i="3211" txt_f="3212">,</offsets><xref rid="B12-nutrients-09-00325" ref-type="bibr"><offsets xml_i="9888" xml_f="9890" txt_i="3212" txt_f="3214">12</offsets></xref><offsets xml_i="9897" xml_f="9898" txt_i="3214" txt_f="3215">,</offsets><xref rid="B13-nutrients-09-00325" ref-type="bibr"><offsets xml_i="9949" xml_f="9951" txt_i="3215" txt_f="3217">13</offsets></xref><offsets xml_i="9958" xml_f="9959" txt_i="3217" txt_f="3218">,</offsets><xref rid="B14-nutrients-09-00325" ref-type="bibr"><offsets xml_i="10010" xml_f="10012" txt_i="3218" txt_f="3220">14</offsets></xref><offsets xml_i="10019" xml_f="10143" txt_i="3220" txt_f="3344">]. These novel lipid mediators provide rationale for further research on the beneficial effects of fish-oil enriched diets. </offsets></p><p><offsets xml_i="10150" xml_f="10165" txt_i="3345" txt_f="3360">Unlikely other </offsets><italic><offsets xml_i="10173" xml_f="10174" txt_i="3360" txt_f="3361">n</offsets></italic><offsets xml_i="10183" xml_f="10216" txt_i="3361" txt_f="3394">-6 PUFAs, ɤ-linolenic acid (C18:3</offsets><italic><offsets xml_i="10224" xml_f="10225" txt_i="3394" txt_f="3395">n</offsets></italic><offsets xml_i="10234" xml_f="10415" txt_i="3395" txt_f="3576">-6, GLA), found mostly in borage, black current seed and evening primrose oil (EPO), exerts anti-inflammatory activity. Namely, it can be converted to dihomo-ɤ-linolenic acid (C20:3</offsets><italic><offsets xml_i="10423" xml_f="10424" txt_i="3576" txt_f="3577">n</offsets></italic><offsets xml_i="10433" xml_f="10618" txt_i="3577" txt_f="3762">-6; DGLA) and further to PGs series-1, another group of eicosanoids with potential anti-inflammatory and immunoregulatory effects. Although these oils also contain linoleic acid (C18:2 </offsets><italic><offsets xml_i="10626" xml_f="10627" txt_i="3762" txt_f="3763">n</offsets></italic><offsets xml_i="10636" xml_f="10788" txt_i="3763" txt_f="3915">-6, LA), a precursor of AA, and some dietary GLA can eventually form AA, studies have shown that anti-inflammatory effects of EPO intake is prevailing [</offsets><xref rid="B6-nutrients-09-00325" ref-type="bibr"><offsets xml_i="10838" xml_f="10839" txt_i="3915" txt_f="3916">6</offsets></xref><offsets xml_i="10846" xml_f="11007" txt_i="3916" txt_f="4077">]. Thus, GLA may also alleviate inflammation and disease severity in patients with RA, as shown in clinical trials using high doses of 1400–2800 mg GLA per day [</offsets><xref rid="B15-nutrients-09-00325" ref-type="bibr"><offsets xml_i="11058" xml_f="11060" txt_i="4077" txt_f="4079">15</offsets></xref><offsets xml_i="11067" xml_f="11068" txt_i="4079" txt_f="4080">,</offsets><xref rid="B16-nutrients-09-00325" ref-type="bibr"><offsets xml_i="11119" xml_f="11121" txt_i="4080" txt_f="4082">16</offsets></xref><offsets xml_i="11128" xml_f="11129" txt_i="4082" txt_f="4083">,</offsets><xref rid="B17-nutrients-09-00325" ref-type="bibr"><offsets xml_i="11180" xml_f="11182" txt_i="4083" txt_f="4085">17</offsets></xref><offsets xml_i="11189" xml_f="11190" txt_i="4085" txt_f="4086">,</offsets><xref rid="B18-nutrients-09-00325" ref-type="bibr"><offsets xml_i="11241" xml_f="11243" txt_i="4086" txt_f="4088">18</offsets></xref><offsets xml_i="11250" xml_f="11251" txt_i="4088" txt_f="4089">,</offsets><xref rid="B19-nutrients-09-00325" ref-type="bibr"><offsets xml_i="11302" xml_f="11304" txt_i="4089" txt_f="4091">19</offsets></xref><offsets xml_i="11311" xml_f="11312" txt_i="4091" txt_f="4092">,</offsets><xref rid="B20-nutrients-09-00325" ref-type="bibr"><offsets xml_i="11363" xml_f="11365" txt_i="4092" txt_f="4094">20</offsets></xref><offsets xml_i="11372" xml_f="11373" txt_i="4094" txt_f="4095">,</offsets><xref rid="B21-nutrients-09-00325" ref-type="bibr"><offsets xml_i="11424" xml_f="11426" txt_i="4095" txt_f="4097">21</offsets></xref><offsets xml_i="11433" xml_f="11434" txt_i="4097" txt_f="4098">,</offsets><xref rid="B22-nutrients-09-00325" ref-type="bibr"><offsets xml_i="11485" xml_f="11487" txt_i="4098" txt_f="4100">22</offsets></xref><offsets xml_i="11494" xml_f="11495" txt_i="4100" txt_f="4101">,</offsets><xref rid="B23-nutrients-09-00325" ref-type="bibr"><offsets xml_i="11546" xml_f="11548" txt_i="4101" txt_f="4103">23</offsets></xref><offsets xml_i="11555" xml_f="11557" txt_i="4103" txt_f="4105">].</offsets></p><p><offsets xml_i="11564" xml_f="11820" txt_i="4106" txt_f="4362">Although many studies have addressed fish oil supplementation in RA patients, the results are inconsistent. Large doses of at least 2.7 g EPA + DHA are likely required to achieve desirable outcomes in RA, but these doses can increase the risk of bleeding [</offsets><xref rid="B24-nutrients-09-00325" ref-type="bibr"><offsets xml_i="11871" xml_f="11873" txt_i="4362" txt_f="4364">24</offsets></xref><offsets xml_i="11880" xml_f="11940" txt_i="4364" txt_f="4424">]. In this study, RA patients were supplemented either with </offsets><italic><offsets xml_i="11948" xml_f="11949" txt_i="4424" txt_f="4425">n</offsets></italic><offsets xml_i="11958" xml_f="11969" txt_i="4425" txt_f="4436">-3 PUFA or </offsets><italic><offsets xml_i="11977" xml_f="11978" txt_i="4436" txt_f="4437">n</offsets></italic><offsets xml_i="11987" xml_f="12205" txt_i="4437" txt_f="4655">-3 PUFA and GLA to examine possible anti-inflammatory effects and clinical benefits compared to the control group of patients, who had no supplementation. We also tested the possible synergistic effect of the combined </offsets><italic><offsets xml_i="12213" xml_f="12214" txt_i="4655" txt_f="4656">n</offsets></italic><offsets xml_i="12223" xml_f="12582" txt_i="4656" txt_f="5015">-3 PUFA + GLA supplementation. Our primary outcome measures were the alterations of PUFA in plasma phospholipids, with emphasis on EPA, DGLA and AA, that would indicate changes in the eicosanoids generation. The secondary outcome measure was the level of disease activity as measured with the DAS 28 disease activity score and the visual analogue scale (VAS).</offsets></p></sec><sec id="sec2-nutrients-09-00325"><title><offsets xml_i="12633" xml_f="12658" txt_i="5017" txt_f="5042">2. Materials and Methods </offsets></title><p><offsets xml_i="12669" xml_f="12966" txt_i="5043" txt_f="5340">This prospective, double-blind randomized-controlled trial included 60 female patients (mean age 63.1 ± 9.6 years) with RA, recruited at the Rheumatology Department, Clinical Center Kragujevac, Serbia, in 2014. RA was diagnosed based on the American College of Rheumatology 2010 revised criteria [</offsets><xref rid="B25-nutrients-09-00325" ref-type="bibr"><offsets xml_i="13017" xml_f="13019" txt_i="5340" txt_f="5342">25</offsets></xref><offsets xml_i="13026" xml_f="13788" txt_i="5342" txt_f="6101">]. The mean duration (± standard deviation) of the disease was 59 ± 60 months (12–180 months). All patients had the same anti-rheumatic therapy. Changes in the treatment regime (dose/type of drug, etc.) were predetermined exclusion criteria. Patients received low doses of corticosteroids (&lt;10 mg/day), oral methotrexate (mean dose 15 mg/week) and folic acid 10 mg/week, while nonsteroidal anti-inflammatory drugs (NSAIDs) were given occasionally. Patients were eligible if the dosage of NSAIDs and/or corticosteroids had been constant for at least one month at the recruitment, and remained unchanged during the study, while the dose of disease-modifying antirheumatic drugs (DMARDs) had to be stable for at least two months before and throughout the trial. </offsets></p><p><offsets xml_i="13795" xml_f="13920" txt_i="6102" txt_f="6227">Patients were randomly allocated to three groups of 20 patients. The first group was taking 5 g of fish oil (5 Omega-3 Cardio</offsets><sup><offsets xml_i="13925" xml_f="13926" txt_i="6227" txt_f="6228">®</offsets></sup><offsets xml_i="13932" xml_f="14093" txt_i="6228" txt_f="6389"> gel capsules, Natural Wealth, NBTY Inc., New York, NY, USA; each containing 1 g of concentrated fish oil with 300 mg of DHA, 200 mg of EPA, and 100 mg of other </offsets><italic><offsets xml_i="14101" xml_f="14102" txt_i="6389" txt_f="6390">n</offsets></italic><offsets xml_i="14111" xml_f="14182" txt_i="6390" txt_f="6461">-3 PUFAs) daily after meals. The second group received 2 Omega-3 Cardio</offsets><sup><offsets xml_i="14187" xml_f="14188" txt_i="6461" txt_f="6462">®</offsets></sup><offsets xml_i="14194" xml_f="14236" txt_i="6462" txt_f="6504"> gel capsules and two Evening Primrose Oil</offsets><sup><offsets xml_i="14241" xml_f="14242" txt_i="6504" txt_f="6505">®</offsets></sup><offsets xml_i="14248" xml_f="14561" txt_i="6505" txt_f="6818"> gel capsules (Natural Wealth, NBTY Inc., New York, NY, USA; one gel capsule contains 1300 mg of evening primrose oil (Oenotherabiennis, seed) with 949 mg of LA and 117 mg of GLA) daily after meals, and the third group received only the previously described rheumatologic therapy, representing the control group. </offsets></p><p><offsets xml_i="14568" xml_f="15227" txt_i="6819" txt_f="7478">For the clinical evaluation of RA, we used the disease activity score (DAS) 28, which includes the 28 different joints for calculation (proximal interphalangeal joints, metacarpophalangeal joints, wrists, elbows, shoulders, and knees). The DAS 28 also takes into account the erythrocyte sedimentation rate (ESR) and the visual analogue scale (VAS) score. The VAS used a 100-mm horizontal scale where patients were asked to report the current pain intensity, by placing a line on a VAS scale between “no pain” (left end, 0 mm) and “excruciating pain” (right end 100 mm). The DAS 28 score calculation was performed by the automatic DAS 28 calculator V1.1-beta [</offsets><xref rid="B26-nutrients-09-00325" ref-type="bibr"><offsets xml_i="15278" xml_f="15280" txt_i="7478" txt_f="7480">26</offsets></xref><offsets xml_i="15287" xml_f="15290" txt_i="7480" txt_f="7483">]. </offsets></p><p><offsets xml_i="15297" xml_f="15609" txt_i="7484" txt_f="7796">Laboratory tests and clinical evaluations were performed on two occasions: before the treatments were administered and three months after the beginning of the study. No patients dropped out from the study and compliance was checked at the end of each month by the researchers, who counted the number of capsules.</offsets></p><sec id="sec2dot1-nutrients-09-00325"><title><offsets xml_i="15658" xml_f="15678" txt_i="7797" txt_f="7817">2.1. Adverse Effects</offsets></title><p><offsets xml_i="15689" xml_f="16010" txt_i="7818" txt_f="8139">Adverse effects related to the study treatment were mild and their rate was similar in the two intervention groups. Mild gastrointestinal discomfort (mild diarrhoea, abdominal pain, dyspepsia or nausea lasting less than 72 h) that did not require any additional intervention, was noted in two patients in the first group.</offsets></p><p><offsets xml_i="16017" xml_f="16816" txt_i="8140" txt_f="8939">The following exclusion criteria were used: serious chronic renal, liver or heart diseases, diabetes mellitus, smoking habit (in the last five years), uncontrolled hypertension, hyperlipidaemia, a family history of cardiovascular disease, premature menopause, a severe folic acid, vitamin B6 or vitamin B12 deficiency, and other forms of arthritis apart from RA. Clinical evaluations included anthropometric measurements (height, weight). Standing height was measured without shoes on a wall-mounted stadiometer (Perspective Enterprises, Kalamazoo, MI, USA). Body weight, body mass index (BMI), and body fat percent were measured with a Tanita body composition analyser (TBF-300, Tanita Corp., Tokyo, Japan). Written informed consent was obtained from all study participants prior to the enrolment. </offsets></p><p><offsets xml_i="16823" xml_f="17026" txt_i="8940" txt_f="9143">The study was approved by the Ethical Committee, Clinical Center, Kragujevac, Serbia, No 01/543-21.01.2014. This study has been conducted in accordance with the principles of the Declaration of Helsinki.</offsets></p></sec><sec id="sec2dot2-nutrients-09-00325"><title><offsets xml_i="17081" xml_f="17126" txt_i="9145" txt_f="9190">2.2. Fatty Acid (FA) Extraction and Analysis </offsets></title><p><offsets xml_i="17137" xml_f="17312" txt_i="9191" txt_f="9366">Venous blood samples were taken after 12 h of fasting at the beginning of the study and after 12 weeks of intervention. The method using a chloroform to methanol mixture (2:1 </offsets><italic><offsets xml_i="17320" xml_f="17321" txt_i="9366" txt_f="9367">v</offsets></italic><offsets xml_i="17330" xml_f="17331" txt_i="9367" txt_f="9368">/</offsets><italic><offsets xml_i="17339" xml_f="17340" txt_i="9368" txt_f="9369">v</offsets></italic><offsets xml_i="17349" xml_f="17509" txt_i="9369" txt_f="9529">) as a solvent and 2,6-di-tert-butyl-4-methylphenol (BHT, 10 mg/100 mL) as an antioxidant, was applied to extract total plasma lipids, as described previously [</offsets><xref rid="B27-nutrients-09-00325" ref-type="bibr"><offsets xml_i="17560" xml_f="17562" txt_i="9529" txt_f="9531">27</offsets></xref><offsets xml_i="17569" xml_f="17779" txt_i="9531" txt_f="9741">]. In the next step, the phospholipid (PL) fraction was separated from other lipid subclasses via silica thin-layer chromatography in a neutral solvent system (petrol ether: diethyl ether: acetic acid, 87:12:1 </offsets><italic><offsets xml_i="17787" xml_f="17788" txt_i="9741" txt_f="9742">v</offsets></italic><offsets xml_i="17797" xml_f="17798" txt_i="9742" txt_f="9743">/</offsets><italic><offsets xml_i="17806" xml_f="17807" txt_i="9743" txt_f="9744">v</offsets></italic><offsets xml_i="17816" xml_f="17969" txt_i="9744" txt_f="9897">). The phospholipids fraction was placed in a screw-capped glass test tubes for methylation. The FA methyl esters were prepared as described previously [</offsets><xref rid="B28-nutrients-09-00325" ref-type="bibr"><offsets xml_i="18020" xml_f="18022" txt_i="9897" txt_f="9899">28</offsets></xref><offsets xml_i="18029" xml_f="18185" txt_i="9899" txt_f="10055">] with slight modifications. In the test tube was added 1.5 mL hexane and 0.2 mL of 2 N NaOH in methanol and heated at 85°C for 1 h, and then 0.2 mL of 1M H</offsets><sub><offsets xml_i="18190" xml_f="18191" txt_i="10055" txt_f="10056">2</offsets></sub><offsets xml_i="18197" xml_f="18199" txt_i="10056" txt_f="10058">SO</offsets><sub><offsets xml_i="18204" xml_f="18205" txt_i="10058" txt_f="10059">4</offsets></sub><offsets xml_i="18211" xml_f="18314" txt_i="10059" txt_f="10162"> in methanol and heated at 85°C for 2 h. After cooling to room temperature and centrifugation on 1860× </offsets><italic><offsets xml_i="18322" xml_f="18323" txt_i="10162" txt_f="10163">g</offsets></italic><offsets xml_i="18332" xml_f="18985" txt_i="10163" txt_f="10816">, for 15 min, the hexane layer was dried under a stream of nitrogen. Prepared methyl esters were dissolved in 10 μL of hexane. Fatty acid (FA) analysis was started with the injection of 1 μL of sample into the gas-liquid chromatography device (Shimadzu GC 2014, flame ionization detector, Rtx 2330 column 60 m × 0.25 mm ID, film thickness 0.2 μm, Restek, Bellefonte, PA, USA). FA were identified according to the retention times of samples in comparison with the standards (Sigma Chemical Co., St. Louis, Missouri, MO, USA) and (PUFA)-2 standard mixture (Restek Co., Bellefonte, Pennsylvania, PA, USA), and expressed as relative percentages of total FA.</offsets></p></sec><sec id="sec2dot3-nutrients-09-00325"><title><offsets xml_i="19040" xml_f="19065" txt_i="10818" txt_f="10843">2.3. Statistical Analysis</offsets></title><p><offsets xml_i="19076" xml_f="19175" txt_i="10844" txt_f="10943">Statistical data analysis was performed using SPSS 20.0 (SPSS Inc., Chicago, IL, USA), considering </offsets><italic><offsets xml_i="19183" xml_f="19184" txt_i="10943" txt_f="10944">p</offsets></italic><offsets xml_i="19193" xml_f="19721" txt_i="10944" txt_f="11472"> ≤ 0.05 as significant. The results are presented as mean ± SD. The Kolmogorov-Smirnov test was applied to confirm the distribution of the data. Differences among the three tested groups at baseline and at the end of the study were assessed by one-way ANOVA followed by the Tukey post hoc test or by Kruskal-Wallis and Mann-Whitney U test, depending on the normality. To assess the effects of the supplementations, two-way (group and time) repeated measures ANOVA, was applied, with Bonferroni post hoc tests, where appropriate.</offsets></p></sec></sec><sec id="sec3-nutrients-09-00325"><title><offsets xml_i="19778" xml_f="19788" txt_i="11475" txt_f="11485">3. Results</offsets></title><p><offsets xml_i="19799" xml_f="20079" txt_i="11486" txt_f="11766">Patients were randomly divided into three groups, which were receiving the same anti-rheumatic therapy. During 12 weeks, the first group took fish oil, the second one took fish oil + EPO and the third one did not take supplements. Patients’ basic characteristics are presented in </offsets><xref ref-type="table" rid="nutrients-09-00325-t001"><offsets xml_i="20132" xml_f="20139" txt_i="11766" txt_f="11773">Table 1</offsets></xref><offsets xml_i="20146" xml_f="20211" txt_i="11773" txt_f="11838">. Age, BMI and the duration of RA were similar among the groups (</offsets><xref ref-type="table" rid="nutrients-09-00325-t001"><offsets xml_i="20264" xml_f="20271" txt_i="11838" txt_f="11845">Table 1</offsets></xref><offsets xml_i="20278" xml_f="20281" txt_i="11845" txt_f="11848">). </offsets></p><p><offsets xml_i="20288" xml_f="20392" txt_i="11849" txt_f="11953">A significant decrease in the DAS 28 score was found in the fish oil group (4.99 ± 0.88 to 3.91 ± 0.80, </offsets><italic><offsets xml_i="20400" xml_f="20401" txt_i="11953" txt_f="11954">p</offsets></italic><offsets xml_i="20410" xml_f="20459" txt_i="11954" txt_f="12000"> &lt; 0.001, group I) and in the group II taking </offsets><italic><offsets xml_i="20467" xml_f="20468" txt_i="12000" txt_f="12001">n</offsets></italic><offsets xml_i="20477" xml_f="20631" txt_i="12001" txt_f="12155">-3 PUFA and EPO (4.76 ± 0.85 to 3.79 ± 0.72, group II). The DAS 28 score in group III trended towards a significant decrease (4.66 ± 0.80 to 4.23 ± 0.66, </offsets><italic><offsets xml_i="20639" xml_f="20640" txt_i="12155" txt_f="12156">p</offsets></italic><offsets xml_i="20649" xml_f="20660" txt_i="12156" txt_f="12167"> = 0.053) (</offsets><xref ref-type="table" rid="nutrients-09-00325-t002"><offsets xml_i="20713" xml_f="20720" txt_i="12167" txt_f="12174">Table 2</offsets></xref><offsets xml_i="20727" xml_f="20729" txt_i="12174" txt_f="12176">).</offsets></p><p><offsets xml_i="20736" xml_f="20836" txt_i="12177" txt_f="12277">The number of painful joints and VAS score significantly decreased in both the supplemented groups (</offsets><italic><offsets xml_i="20844" xml_f="20845" txt_i="12277" txt_f="12278">p</offsets></italic><offsets xml_i="20854" xml_f="20910" txt_i="12278" txt_f="12334"> ≤ 0.001) after 12 weeks, but not in the control group (</offsets><xref ref-type="table" rid="nutrients-09-00325-t002"><offsets xml_i="20963" xml_f="20970" txt_i="12334" txt_f="12341">Table 2</offsets></xref><offsets xml_i="20977" xml_f="20979" txt_i="12341" txt_f="12343">).</offsets></p><p><offsets xml_i="20986" xml_f="21033" txt_i="12344" txt_f="12391">Because of the high fish oil intake, EPA, DHA, </offsets><italic><offsets xml_i="21041" xml_f="21042" txt_i="12391" txt_f="12392">n</offsets></italic><offsets xml_i="21051" xml_f="21099" txt_i="12392" txt_f="12440">-3 PUFA and total PUFA increased significantly (</offsets><italic><offsets xml_i="21107" xml_f="21108" txt_i="12440" txt_f="12441">p</offsets></italic><offsets xml_i="21117" xml_f="21126" txt_i="12441" txt_f="12450"> ≤ 0.05, </offsets><xref ref-type="table" rid="nutrients-09-00325-t003"><offsets xml_i="21179" xml_f="21186" txt_i="12450" txt_f="12457">Table 3</offsets></xref><offsets xml_i="21193" xml_f="21239" txt_i="12457" txt_f="12503">) in plasma of the group I. Additionally, the </offsets><italic><offsets xml_i="21247" xml_f="21248" txt_i="12503" txt_f="12504">n</offsets></italic><offsets xml_i="21257" xml_f="21260" txt_i="12504" txt_f="12507">-6/</offsets><italic><offsets xml_i="21268" xml_f="21269" txt_i="12507" txt_f="12508">n</offsets></italic><offsets xml_i="21278" xml_f="21333" txt_i="12508" txt_f="12563">-3 PUFA ratio and MUFA, especially vaccenic acid (C18:1</offsets><italic><offsets xml_i="21341" xml_f="21342" txt_i="12563" txt_f="12564">n</offsets></italic><offsets xml_i="21351" xml_f="21375" txt_i="12564" txt_f="12588">-7) markedly decreased (</offsets><xref ref-type="table" rid="nutrients-09-00325-t003"><offsets xml_i="21428" xml_f="21435" txt_i="12588" txt_f="12595">Table 3</offsets></xref><offsets xml_i="21442" xml_f="21444" txt_i="12595" txt_f="12597">).</offsets></p><p><offsets xml_i="21451" xml_f="21570" txt_i="12598" txt_f="12717">In the group that ingested 2 g of fish oil + 2.6 g EPO/day (group II), the concentrations of GLA and AA (18:3 and 20:4 </offsets><italic><offsets xml_i="21578" xml_f="21579" txt_i="12717" txt_f="12718">n</offsets></italic><offsets xml_i="21588" xml_f="21628" txt_i="12718" txt_f="12758">-6) significantly increased, as well as </offsets><italic><offsets xml_i="21636" xml_f="21637" txt_i="12758" txt_f="12759">n</offsets></italic><offsets xml_i="21646" xml_f="21664" txt_i="12759" txt_f="12777">-3 EPA, DPA, DHA, </offsets><italic><offsets xml_i="21672" xml_f="21673" txt_i="12777" txt_f="12778">n</offsets></italic><offsets xml_i="21682" xml_f="21707" txt_i="12778" txt_f="12803">-3 PUFA, and total PUFA (</offsets><xref ref-type="table" rid="nutrients-09-00325-t004"><offsets xml_i="21760" xml_f="21767" txt_i="12803" txt_f="12810">Table 4</offsets></xref><offsets xml_i="21774" xml_f="21817" txt_i="12810" txt_f="12853">). In line with this, level of SFA and the </offsets><italic><offsets xml_i="21825" xml_f="21826" txt_i="12853" txt_f="12854">n</offsets></italic><offsets xml_i="21835" xml_f="21838" txt_i="12854" txt_f="12857">-6/</offsets><italic><offsets xml_i="21846" xml_f="21847" txt_i="12857" txt_f="12858">n</offsets></italic><offsets xml_i="21856" xml_f="21922" txt_i="12858" txt_f="12924">-3 PUFA ratio were significantly lower after the supplementation (</offsets><xref ref-type="table" rid="nutrients-09-00325-t004"><offsets xml_i="21975" xml_f="21982" txt_i="12924" txt_f="12931">Table 4</offsets></xref><offsets xml_i="21989" xml_f="21991" txt_i="12931" txt_f="12933">).</offsets></p><p><offsets xml_i="21998" xml_f="22146" txt_i="12934" txt_f="13082">In the group III (patients without supplementation), no significant changes in FA proportions were found between baseline and the end of the trial (</offsets><xref ref-type="table" rid="nutrients-09-00325-t005"><offsets xml_i="22199" xml_f="22206" txt_i="13082" txt_f="13089">Table 5</offsets></xref><offsets xml_i="22213" xml_f="22215" txt_i="13089" txt_f="13091">).</offsets></p><p><offsets xml_i="22222" xml_f="22311" txt_i="13092" txt_f="13181">After 12 weeks of supplementation, when all groups were compared, levels of EPA, DHA and </offsets><italic><offsets xml_i="22319" xml_f="22320" txt_i="13181" txt_f="13182">n</offsets></italic><offsets xml_i="22329" xml_f="22358" txt_i="13182" txt_f="13211">-3 PUFA were higher, and the </offsets><italic><offsets xml_i="22366" xml_f="22367" txt_i="13211" txt_f="13212">n</offsets></italic><offsets xml_i="22376" xml_f="22382" txt_i="13212" txt_f="13218">-6 to </offsets><italic><offsets xml_i="22390" xml_f="22391" txt_i="13218" txt_f="13219">n</offsets></italic><offsets xml_i="22400" xml_f="22563" txt_i="13219" txt_f="13382">-3 ratio was lower in both supplemented groups than in the control patients. GLA and AA were higher in the group II (fish oil + EPO) than in the groups I and III (</offsets><xref ref-type="table" rid="nutrients-09-00325-t006"><offsets xml_i="22616" xml_f="22623" txt_i="13382" txt_f="13389">Table 6</offsets></xref><offsets xml_i="22630" xml_f="22632" txt_i="13389" txt_f="13391">).</offsets></p><p><offsets xml_i="22639" xml_f="22755" txt_i="13392" txt_f="13508">A repeated measures ANOVA revealed significant time × group interactions for the following FAs: stearic acid (18:0, </offsets><italic><offsets xml_i="22763" xml_f="22764" txt_i="13508" txt_f="13509">p</offsets></italic><offsets xml_i="22773" xml_f="22803" txt_i="13509" txt_f="13539"> = 0.034), vaccenic acid (18:1</offsets><italic><offsets xml_i="22811" xml_f="22812" txt_i="13539" txt_f="13540">n</offsets></italic><offsets xml_i="22821" xml_f="22825" txt_i="13540" txt_f="13544">-7, </offsets><italic><offsets xml_i="22833" xml_f="22834" txt_i="13544" txt_f="13545">p</offsets></italic><offsets xml_i="22843" xml_f="22864" txt_i="13545" txt_f="13566"> = 0.010), and MUFA (</offsets><italic><offsets xml_i="22872" xml_f="22873" txt_i="13566" txt_f="13567">p</offsets></italic><offsets xml_i="22882" xml_f="22892" txt_i="13567" txt_f="13577"> = 0.028).</offsets></p></sec><sec id="sec4-nutrients-09-00325"><title><offsets xml_i="22943" xml_f="22956" txt_i="13579" txt_f="13592">4. Discussion</offsets></title><p><offsets xml_i="22967" xml_f="23067" txt_i="13593" txt_f="13693">Fatty acids found in plasma phospholipids reflect food intake over the last several days and weeks [</offsets><xref rid="B29-nutrients-09-00325" ref-type="bibr"><offsets xml_i="23118" xml_f="23120" txt_i="13693" txt_f="13695">29</offsets></xref><offsets xml_i="23127" xml_f="23155" txt_i="13695" txt_f="13723">] as well as FA metabolism [</offsets><xref rid="B30-nutrients-09-00325" ref-type="bibr"><offsets xml_i="23206" xml_f="23208" txt_i="13723" txt_f="13725">30</offsets></xref><offsets xml_i="23215" xml_f="23299" txt_i="13725" txt_f="13809">]. Altered FA composition was reported in many pathologic and physiological states [</offsets><xref rid="B30-nutrients-09-00325" ref-type="bibr"><offsets xml_i="23350" xml_f="23352" txt_i="13809" txt_f="13811">30</offsets></xref><offsets xml_i="23359" xml_f="23360" txt_i="13811" txt_f="13812">,</offsets><xref rid="B31-nutrients-09-00325" ref-type="bibr"><offsets xml_i="23411" xml_f="23413" txt_i="13812" txt_f="13814">31</offsets></xref><offsets xml_i="23420" xml_f="23421" txt_i="13814" txt_f="13815">,</offsets><xref rid="B32-nutrients-09-00325" ref-type="bibr"><offsets xml_i="23472" xml_f="23474" txt_i="13815" txt_f="13817">32</offsets></xref><offsets xml_i="23481" xml_f="23482" txt_i="13817" txt_f="13818">,</offsets><xref rid="B33-nutrients-09-00325" ref-type="bibr"><offsets xml_i="23533" xml_f="23535" txt_i="13818" txt_f="13820">33</offsets></xref><offsets xml_i="23542" xml_f="23577" txt_i="13820" txt_f="13855">], including chronic inflammation [</offsets><xref rid="B34-nutrients-09-00325" ref-type="bibr"><offsets xml_i="23628" xml_f="23630" txt_i="13855" txt_f="13857">34</offsets></xref><offsets xml_i="23637" xml_f="23729" txt_i="13857" txt_f="13949">]. However, FA profiles and the course of diseases can be affected by PUFA supplementation [</offsets><xref rid="B35-nutrients-09-00325" ref-type="bibr"><offsets xml_i="23780" xml_f="23782" txt_i="13949" txt_f="13951">35</offsets></xref><offsets xml_i="23789" xml_f="23790" txt_i="13951" txt_f="13952">,</offsets><xref rid="B36-nutrients-09-00325" ref-type="bibr"><offsets xml_i="23841" xml_f="23843" txt_i="13952" txt_f="13954">36</offsets></xref><offsets xml_i="23850" xml_f="23969" txt_i="13954" txt_f="14073">]. In this study, the levels of supplemented PUFA in plasma increased in the groups I and II depending on the dosages (</offsets><xref ref-type="table" rid="nutrients-09-00325-t003"><offsets xml_i="24022" xml_f="24029" txt_i="14073" txt_f="14080">Table 3</offsets></xref><offsets xml_i="24036" xml_f="24041" txt_i="14080" txt_f="14085"> and </offsets><xref ref-type="table" rid="nutrients-09-00325-t004"><offsets xml_i="24094" xml_f="24101" txt_i="14085" txt_f="14092">Table 4</offsets></xref><offsets xml_i="24108" xml_f="24350" txt_i="14092" txt_f="14334">), demonstrating a good patient compliance and bioavailability of the supplements. The changes in FA composition in response to the supplementation (groups I and II) confirmed that plasma phospholipids are reliable biomarkers for fat intake (</offsets><xref ref-type="table" rid="nutrients-09-00325-t003"><offsets xml_i="24403" xml_f="24410" txt_i="14334" txt_f="14341">Table 3</offsets></xref><offsets xml_i="24417" xml_f="24422" txt_i="14341" txt_f="14346"> and </offsets><xref ref-type="table" rid="nutrients-09-00325-t004"><offsets xml_i="24475" xml_f="24482" txt_i="14346" txt_f="14353">Table 4</offsets></xref><offsets xml_i="24489" xml_f="24525" txt_i="14353" txt_f="14389">). In particular, it can be seen in </offsets><xref ref-type="table" rid="nutrients-09-00325-t006"><offsets xml_i="24578" xml_f="24585" txt_i="14389" txt_f="14396">Table 6</offsets></xref><offsets xml_i="24592" xml_f="24715" txt_i="14396" txt_f="14519">, where the differences among the three groups after supplementation were most significant for FA used for supplementation.</offsets></p><p><offsets xml_i="24722" xml_f="25018" txt_i="14520" txt_f="14816">The results have shown improvements in several laboratory and clinical parameters in RA patients with the active disease, who were taking anti-inflammatory oils along with the standard therapy. The consumption of 5 g of fish oil by the patients in group I resulted in significantly elevated EPA (</offsets><xref ref-type="table" rid="nutrients-09-00325-t003"><offsets xml_i="25071" xml_f="25078" txt_i="14816" txt_f="14823">Table 3</offsets></xref><offsets xml_i="25085" xml_f="25661" txt_i="14823" txt_f="15399">). The AA content in phospholipids is a regulator of the biosynthesis of the proinflammatory prostanoids and leukotriens, whereas EPA has the opposite effect. Therefore, the AA/EPA ratio determines the degree of inflammation. Additionally, EPA and DHA support the synthesis of proresolving mediators such as protectins, resolvins, and maresins. Accordingly, a significant improvement in clinical variables, the severity of pain, the number of swollen/tender joints, as well as disease activity parameters (DAS 28 and VAS scores), were also observed in the supplemented group. </offsets></p><p><offsets xml_i="25668" xml_f="25744" txt_i="15400" txt_f="15476">In a 24-week study, Berbert et al. supplemented RA patients with 3 g/day of </offsets><italic><offsets xml_i="25752" xml_f="25753" txt_i="15476" txt_f="15477">n</offsets></italic><offsets xml_i="25762" xml_f="25884" txt_i="15477" txt_f="15599">-3 FA (1.8 g EPA and 1.2 g DHA) and found reduced pain and morning stiffness as well as better patient global assessment [</offsets><xref rid="B37-nutrients-09-00325" ref-type="bibr"><offsets xml_i="25935" xml_f="25937" txt_i="15599" txt_f="15601">37</offsets></xref><offsets xml_i="25944" xml_f="26015" txt_i="15601" txt_f="15672">]. The others reported that daily supplementation of approximately 3 g </offsets><italic><offsets xml_i="26023" xml_f="26024" txt_i="15672" txt_f="15673">n</offsets></italic><offsets xml_i="26033" xml_f="26131" txt_i="15673" txt_f="15771">-3 PUFA for about three months was sufficient to achieve clinical improvements in these patients [</offsets><xref rid="B38-nutrients-09-00325" ref-type="bibr"><offsets xml_i="26182" xml_f="26184" txt_i="15771" txt_f="15773">38</offsets></xref><offsets xml_i="26191" xml_f="26192" txt_i="15773" txt_f="15774">,</offsets><xref rid="B39-nutrients-09-00325" ref-type="bibr"><offsets xml_i="26243" xml_f="26245" txt_i="15774" txt_f="15776">39</offsets></xref><offsets xml_i="26252" xml_f="26310" txt_i="15776" txt_f="15834">]. However, some meta-analyses have revealed no effect of </offsets><italic><offsets xml_i="26318" xml_f="26319" txt_i="15834" txt_f="15835">n</offsets></italic><offsets xml_i="26328" xml_f="26441" txt_i="15835" txt_f="15948">-3 PUFAs intake on the inflammation of joints, other clinical variables or the global assessment of RA patients [</offsets><xref rid="B40-nutrients-09-00325" ref-type="bibr"><offsets xml_i="26492" xml_f="26494" txt_i="15948" txt_f="15950">40</offsets></xref><offsets xml_i="26501" xml_f="26502" txt_i="15950" txt_f="15951">,</offsets><xref rid="B41-nutrients-09-00325" ref-type="bibr"><offsets xml_i="26553" xml_f="26555" txt_i="15951" txt_f="15953">41</offsets></xref><offsets xml_i="26562" xml_f="26655" txt_i="15953" txt_f="16046">]. In this regard, our study gives substantial contribution to recommendation for the use of </offsets><italic><offsets xml_i="26663" xml_f="26664" txt_i="16046" txt_f="16047">n</offsets></italic><offsets xml_i="26673" xml_f="26696" txt_i="16047" txt_f="16070">-3 PUFA in RA patients.</offsets></p><p><offsets xml_i="26703" xml_f="26765" txt_i="16071" txt_f="16133">The combination of fish oil and EPO led to an increase in AA (</offsets><xref ref-type="table" rid="nutrients-09-00325-t004"><offsets xml_i="26818" xml_f="26825" txt_i="16133" txt_f="16140">Table 4</offsets></xref><offsets xml_i="26832" xml_f="26938" txt_i="16140" txt_f="16246">). Namely, dietary GLA can be elongated to DGLA and subsequently desaturated to AA by delta-5 desaturase [</offsets><xref rid="B42-nutrients-09-00325" ref-type="bibr"><offsets xml_i="26989" xml_f="26991" txt_i="16246" txt_f="16248">42</offsets></xref><offsets xml_i="26998" xml_f="27098" txt_i="16248" txt_f="16348">]. Hence, a slight increase of the AA content in phospholipids after GLA supplementation (group II; </offsets><xref ref-type="table" rid="nutrients-09-00325-t004"><offsets xml_i="27151" xml_f="27158" txt_i="16348" txt_f="16355">Table 4</offsets></xref><offsets xml_i="27165" xml_f="27646" txt_i="16355" txt_f="16836">) was expected. In addition, LA as the main precursor for AA synthesis, was also presented in EPO capsules. Nevertheless, in our study supplementation with both fish oil and EPO resulted in significantly improved clinical variables, the severity of pain and the number of swollen and/or tender joints. These results indicate that the anti-inflammatory potential of GLA and DGLA, including the synthesis of PG series 1, are more pronounced than the conversion into inflammatory AA. </offsets></p><p><offsets xml_i="27653" xml_f="27667" txt_i="16837" txt_f="16851">The intake of </offsets><italic><offsets xml_i="27675" xml_f="27676" txt_i="16851" txt_f="16852">n</offsets></italic><offsets xml_i="27685" xml_f="27828" txt_i="16852" txt_f="16995">-6 LA was usually not controlled in studies on patients with RA. LA is ultimately converted into AA and further to pro-inflammatory cytokines [</offsets><xref rid="B40-nutrients-09-00325" ref-type="bibr"><offsets xml_i="27879" xml_f="27881" txt_i="16995" txt_f="16997">40</offsets></xref><offsets xml_i="27888" xml_f="27899" txt_i="16997" txt_f="17008">]. PUFA of </offsets><italic><offsets xml_i="27907" xml_f="27908" txt_i="17008" txt_f="17009">n</offsets></italic><offsets xml_i="27917" xml_f="27983" txt_i="17009" txt_f="17075">-3 series can diminish this conversion by competitive inhibition [</offsets><xref rid="B43-nutrients-09-00325" ref-type="bibr"><offsets xml_i="28034" xml_f="28036" txt_i="17075" txt_f="17077">43</offsets></xref><offsets xml_i="28043" xml_f="28131" txt_i="17077" txt_f="17165">]. It has also been proposed that restricting AA intake is required to benefit from the </offsets><italic><offsets xml_i="28139" xml_f="28140" txt_i="17165" txt_f="17166">n</offsets></italic><offsets xml_i="28149" xml_f="28175" txt_i="17166" txt_f="17192">-3 intake in RA patients [</offsets><xref rid="B44-nutrients-09-00325" ref-type="bibr"><offsets xml_i="28226" xml_f="28228" txt_i="17192" txt_f="17194">44</offsets></xref><offsets xml_i="28235" xml_f="28348" txt_i="17194" txt_f="17307">]. Additional studies addressing plasma lipids and patient compliance measurements should confirm these findings.</offsets></p><p><offsets xml_i="28355" xml_f="28415" txt_i="17308" txt_f="17368">Numerous investigations have shown the relationship between </offsets><italic><offsets xml_i="28423" xml_f="28424" txt_i="17368" txt_f="17369">n</offsets></italic><offsets xml_i="28433" xml_f="28491" txt_i="17369" txt_f="17427">-3 PUFA consumption and reducing inflammatory parameters [</offsets><xref rid="B40-nutrients-09-00325" ref-type="bibr"><offsets xml_i="28542" xml_f="28544" txt_i="17427" txt_f="17429">40</offsets></xref><offsets xml_i="28551" xml_f="28552" txt_i="17429" txt_f="17430">,</offsets><xref rid="B41-nutrients-09-00325" ref-type="bibr"><offsets xml_i="28603" xml_f="28605" txt_i="17430" txt_f="17432">41</offsets></xref><offsets xml_i="28612" xml_f="28613" txt_i="17432" txt_f="17433">,</offsets><xref rid="B45-nutrients-09-00325" ref-type="bibr"><offsets xml_i="28664" xml_f="28666" txt_i="17433" txt_f="17435">45</offsets></xref><offsets xml_i="28673" xml_f="28674" txt_i="17435" txt_f="17436">,</offsets><xref rid="B46-nutrients-09-00325" ref-type="bibr"><offsets xml_i="28725" xml_f="28727" txt_i="17436" txt_f="17438">46</offsets></xref><offsets xml_i="28734" xml_f="28847" txt_i="17438" txt_f="17551">]. Here we found lower ESR in group I and II than in the control patients, which was in line with other studies [</offsets><xref rid="B37-nutrients-09-00325" ref-type="bibr"><offsets xml_i="28898" xml_f="28900" txt_i="17551" txt_f="17553">37</offsets></xref><offsets xml_i="28907" xml_f="28908" txt_i="17553" txt_f="17554">,</offsets><xref rid="B47-nutrients-09-00325" ref-type="bibr"><offsets xml_i="28959" xml_f="28961" txt_i="17554" txt_f="17556">47</offsets></xref><offsets xml_i="28968" xml_f="28997" txt_i="17556" txt_f="17585">]. However, the link between </offsets><italic><offsets xml_i="29005" xml_f="29006" txt_i="17585" txt_f="17586">n</offsets></italic><offsets xml_i="29015" xml_f="29107" txt_i="17586" txt_f="17678">-3 PUFA and CRP is unclear. For instance, a 12-week supplementation with different doses of </offsets><italic><offsets xml_i="29115" xml_f="29116" txt_i="17678" txt_f="17679">n</offsets></italic><offsets xml_i="29125" xml_f="29234" txt_i="17679" txt_f="17788">-3 FA (1.5–6 g/day) did not decrease CRP concentrations when compared to the placebo group, as in our study [</offsets><xref rid="B48-nutrients-09-00325" ref-type="bibr"><offsets xml_i="29285" xml_f="29287" txt_i="17788" txt_f="17790">48</offsets></xref><offsets xml_i="29294" xml_f="29361" txt_i="17790" txt_f="17857">]. It seems that inconsistent results come from different doses of </offsets><italic><offsets xml_i="29369" xml_f="29370" txt_i="17857" txt_f="17858">n</offsets></italic><offsets xml_i="29379" xml_f="29586" txt_i="17858" txt_f="18065">-3 PUFA needed for different inflammatory markers. Besides, we have shown that the consumption of fish oil combined with EPO also had positive effects in patients with RA, which were similar or even better (</offsets><xref ref-type="table" rid="nutrients-09-00325-t002"><offsets xml_i="29639" xml_f="29646" txt_i="18065" txt_f="18072">Table 2</offsets></xref><offsets xml_i="29653" xml_f="29824" txt_i="18072" txt_f="18243">) than the fish oil supplementation alone. Thus, this combination has a great potential as an adjuvant therapy in patients with RA and other chronic inflammatory diseases.</offsets></p><p><offsets xml_i="29831" xml_f="29996" txt_i="18244" txt_f="18409">Furthermore, chronic use of standard DMARDs, especially methotrexate, often leads to cardiovascular problems, that could be alleviated by concomitant consumption of </offsets><italic><offsets xml_i="30004" xml_f="30005" txt_i="18409" txt_f="18410">n</offsets></italic><offsets xml_i="30014" xml_f="30023" txt_i="18410" txt_f="18419">-3 PUFA [</offsets><xref rid="B49-nutrients-09-00325" ref-type="bibr"><offsets xml_i="30074" xml_f="30076" txt_i="18419" txt_f="18421">49</offsets></xref><offsets xml_i="30083" xml_f="30112" txt_i="18421" txt_f="18450">]. As well, intake of 3 g of </offsets><italic><offsets xml_i="30120" xml_f="30121" txt_i="18450" txt_f="18451">n</offsets></italic><offsets xml_i="30130" xml_f="30257" txt_i="18451" txt_f="18578">-3 PUFA markedly increases the AA/EPA ratio and EPA + DHA index, which are highly reliable predictors of sudden cardiac death [</offsets><xref rid="B50-nutrients-09-00325" ref-type="bibr"><offsets xml_i="30308" xml_f="30310" txt_i="18578" txt_f="18580">50</offsets></xref><offsets xml_i="30317" xml_f="30318" txt_i="18580" txt_f="18581">,</offsets><xref rid="B51-nutrients-09-00325" ref-type="bibr"><offsets xml_i="30369" xml_f="30371" txt_i="18581" txt_f="18583">51</offsets></xref><offsets xml_i="30378" xml_f="30379" txt_i="18583" txt_f="18584">,</offsets><xref rid="B52-nutrients-09-00325" ref-type="bibr"><offsets xml_i="30430" xml_f="30432" txt_i="18584" txt_f="18586">52</offsets></xref><offsets xml_i="30439" xml_f="30535" txt_i="18586" txt_f="18682">]. This is an added value, since patients with RA have strongly elevated risk of cardiac death [</offsets><xref rid="B53-nutrients-09-00325" ref-type="bibr"><offsets xml_i="30586" xml_f="30588" txt_i="18682" txt_f="18684">53</offsets></xref><offsets xml_i="30595" xml_f="30596" txt_i="18684" txt_f="18685">,</offsets><xref rid="B54-nutrients-09-00325" ref-type="bibr"><offsets xml_i="30647" xml_f="30649" txt_i="18685" txt_f="18687">54</offsets></xref><offsets xml_i="30656" xml_f="30796" txt_i="18687" txt_f="18827">]. Nevertheless, the exact impact of the control of chronic inflammation on the reduction of cardiovascular mortality should be elucidated [</offsets><xref rid="B41-nutrients-09-00325" ref-type="bibr"><offsets xml_i="30847" xml_f="30849" txt_i="18827" txt_f="18829">41</offsets></xref><offsets xml_i="30856" xml_f="30858" txt_i="18829" txt_f="18831">].</offsets></p><p><offsets xml_i="30865" xml_f="31116" txt_i="18832" txt_f="19083">The weakness of this study is the lack of a blinded placebo-controlled group, which would have made the interpretation of the data stronger. However, placebo capsules typically contain soy oil, corn oil or sunflower oil, which are all rich sources of </offsets><italic><offsets xml_i="31124" xml_f="31125" txt_i="19083" txt_f="19084">n</offsets></italic><offsets xml_i="31134" xml_f="31287" txt_i="19084" txt_f="19237">-6 PUFA. This could influence our results on FA profiles in the control group and must be taken into account in the interpretation of the FA alterations.</offsets></p></sec><sec id="sec5-nutrients-09-00325"><title><offsets xml_i="31338" xml_f="31352" txt_i="19239" txt_f="19253">5. Conclutions</offsets></title><p><offsets xml_i="31363" xml_f="31800" txt_i="19254" txt_f="19691">In conclusion, the intake of fish oil alone or combined with EPO resulted in a higher incorporation of PUFA precursors for the anti-inflammatory lipid mediators in plasma phospholipids. This further induced a significant improvement in the clinical status of patients with rheumatoid arthritis. Further research with a large number of patients over a longer duration is needed to confirm the long-term efficacy of these supplementations.</offsets></p></sec></body><back><ack><title>Acknowledgments</title><p>This study was supported by Grants No. III 41030 and 175043 from the Ministry of Education, Science and Technological Development of the Republic of Serbia.</p></ack><notes><title>Author Contributions</title><p></p></notes><notes notes-type="COI-statement"><title>Conflicts of Interest</title><p>The authors declare no conflict of interest.</p></notes><ref-list><title>References</title><ref id="B1-nutrients-09-00325"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Széles</surname><given-names>L.</given-names></name><name><surname>Töröcsik</surname><given-names>D.</given-names></name><name><surname>Nagy</surname><given-names>L.</given-names></name></person-group><article-title>PPAR gamma in immunity and inflammation: Cell types and diseases</article-title><source>Biochim. Biophys. Acta</source><year>2007</year><volume>1771</volume><fpage>1014</fpage><lpage>1030</lpage><pub-id pub-id-type="doi">10.1016/j.bbalip.2007.02.005</pub-id><pub-id pub-id-type="pmid">17418635</pub-id></element-citation></ref><ref id="B2-nutrients-09-00325"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Giera</surname><given-names>M.</given-names></name><name><surname>Ioan-Facsinay</surname><given-names>A.</given-names></name><name><surname>Toes</surname><given-names>R.</given-names></name><name><surname>Gao</surname><given-names>F.</given-names></name><name><surname>Dalli</surname><given-names>J.</given-names></name><name><surname>Deelder</surname><given-names>A.M.</given-names></name><name><surname>Serhan</surname><given-names>C.N.</given-names></name><name><surname>Mayboroda</surname><given-names>O.A.</given-names></name></person-group><article-title>Lipid and lipid mediator profiling of human synovial fluid in rheumatoid arthritis patients by means of LC-MS/MS</article-title><source>Biochim. Biophys. Acta</source><year>2012</year><volume>1821</volume><fpage>1415</fpage><lpage>1424</lpage><pub-id pub-id-type="doi">10.1016/j.bbalip.2012.07.011</pub-id><pub-id pub-id-type="pmid">22841830</pub-id></element-citation></ref><ref id="B3-nutrients-09-00325"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Woo</surname><given-names>S.J.</given-names></name><name><surname>Lim</surname><given-names>K.</given-names></name><name><surname>Park</surname><given-names>S.Y.</given-names></name><name><surname>Jung</surname><given-names>M.Y.</given-names></name><name><surname>Lim</surname><given-names>H.S.</given-names></name><name><surname>Jeon</surname><given-names>M.G.</given-names></name><name><surname>Lee</surname><given-names>S.I.</given-names></name><name><surname>Park</surname><given-names>B.H.</given-names></name></person-group><article-title>Endogenous conversion of <italic>n</italic>-6 to <italic>n</italic>-3 polyunsaturated fatty acids attenuates K/BxN serum-transfer arthritis in fat-1 mice</article-title><source>J. Nutr. Biochem.</source><year>2015</year><volume>26</volume><fpage>713</fpage><lpage>720</lpage><pub-id pub-id-type="doi">10.1016/j.jnutbio.2015.01.011</pub-id><pub-id pub-id-type="pmid">25910895</pub-id></element-citation></ref><ref id="B4-nutrients-09-00325"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bannenberg</surname><given-names>G.</given-names></name><name><surname>Arita</surname><given-names>M.</given-names></name><name><surname>Serhan</surname><given-names>C.N.</given-names></name></person-group><article-title>Endogenous receptor agonists: Resolving inflammation</article-title><source>Sci. World J.</source><year>2007</year><volume>7</volume><fpage>1440</fpage><lpage>1462</lpage><pub-id pub-id-type="doi">10.1100/tsw.2007.188</pub-id><pub-id pub-id-type="pmid">17767360</pub-id></element-citation></ref><ref id="B5-nutrients-09-00325"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Calder</surname><given-names>P.C.</given-names></name></person-group><article-title><italic>n</italic>-3 polyunsaturated fatty acids, inflammation and inflammatory diseases</article-title><source>Am. J. Clin. Nutr.</source><year>2006</year><volume>83</volume><fpage>1505</fpage><lpage>1519</lpage></element-citation></ref><ref id="B6-nutrients-09-00325"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barden</surname><given-names>A.E.</given-names></name><name><surname>Moghaddami</surname><given-names>M.</given-names></name><name><surname>Mas</surname><given-names>E.</given-names></name><name><surname>Phillips</surname><given-names>M.</given-names></name><name><surname>Cleland</surname><given-names>L.G.</given-names></name><name><surname>Mori</surname><given-names>T.A.</given-names></name></person-group><article-title>Specialised pro-resolving mediators of inflammation in inflammatory arthritis</article-title><source>Prostaglandins Leukot. Essent. Fatty Acids</source><year>2016</year><volume>107</volume><fpage>24</fpage><lpage>29</lpage><pub-id pub-id-type="doi">10.1016/j.plefa.2016.03.004</pub-id><pub-id pub-id-type="pmid">27033423</pub-id></element-citation></ref><ref id="B7-nutrients-09-00325"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Volker</surname><given-names>D.</given-names></name><name><surname>Fitzgerald</surname><given-names>P.</given-names></name><name><surname>Major</surname><given-names>G.</given-names></name><name><surname>Garg</surname><given-names>M.</given-names></name></person-group><article-title>Efficacy of fish oil concentrate in the treatment of rheumatoid arthritis</article-title><source>J. Rheumatol.</source><year>2000</year><volume>27</volume><fpage>2343</fpage><lpage>1346</lpage><pub-id pub-id-type="pmid">11036827</pub-id></element-citation></ref><ref id="B8-nutrients-09-00325"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Calder</surname><given-names>P.C.</given-names></name></person-group><article-title>Dietary modification of inflammation with lipids</article-title><source>Proc. Nutr. Soc.</source><year>2002</year><volume>61</volume><fpage>345</fpage><lpage>358</lpage><pub-id pub-id-type="doi">10.1079/PNS2002166</pub-id><pub-id pub-id-type="pmid">12296294</pub-id></element-citation></ref><ref id="B9-nutrients-09-00325"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mori</surname><given-names>T.A.</given-names></name><name><surname>Beilin</surname><given-names>L.J.</given-names></name></person-group><article-title>Omega-3 fatty acids and inflammation</article-title><source>Curr. Atheroscler. Rep.</source><year>2004</year><volume>6</volume><fpage>461</fpage><lpage>467</lpage><pub-id pub-id-type="doi">10.1007/s11883-004-0087-5</pub-id><pub-id pub-id-type="pmid">15485592</pub-id></element-citation></ref><ref id="B10-nutrients-09-00325"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barden</surname><given-names>A.E.</given-names></name><name><surname>Mas</surname><given-names>E.</given-names></name><name><surname>Mori</surname><given-names>T.A.</given-names></name></person-group><article-title><italic>n</italic>-3 Fatty acid supplementation and proresolving mediators of inflammation</article-title><source>Curr. Opin. Lipidol.</source><year>2016</year><volume>27</volume><fpage>26</fpage><lpage>32</lpage><pub-id pub-id-type="doi">10.1097/MOL.0000000000000262</pub-id><pub-id pub-id-type="pmid">26655290</pub-id></element-citation></ref><ref id="B11-nutrients-09-00325"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dalli</surname><given-names>J.</given-names></name><name><surname>Colas</surname><given-names>R.A.</given-names></name><name><surname>Serhan</surname><given-names>C.N.</given-names></name></person-group><article-title>Novel <italic>n</italic>-3 immunoresolvents: Structures and actions</article-title><source>Sci. Rep.</source><year>2013</year><volume>3</volume><fpage>1940</fpage><pub-id pub-id-type="doi">10.1038/srep01940</pub-id><pub-id pub-id-type="pmid">23736886</pub-id></element-citation></ref><ref id="B12-nutrients-09-00325"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chiang</surname><given-names>N.</given-names></name><name><surname>Serhan</surname><given-names>C.N.</given-names></name></person-group><article-title>Cell-cell interaction in the transcellular biosynthesis of novel omega-3-derived lipid mediators</article-title><source>Methods Mol. Biol.</source><year>2006</year><volume>341</volume><fpage>227</fpage><lpage>250</lpage><pub-id pub-id-type="pmid">16799203</pub-id></element-citation></ref><ref id="B13-nutrients-09-00325"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Serhan</surname><given-names>C.N.</given-names></name><name><surname>Petasis</surname><given-names>N.A.</given-names></name></person-group><article-title>Resolvins and protectins in inflammation resolution</article-title><source>Chem. Rev.</source><year>2011</year><volume>111</volume><fpage>5922</fpage><lpage>5943</lpage><pub-id pub-id-type="doi">10.1021/cr100396c</pub-id><pub-id pub-id-type="pmid">21766791</pub-id></element-citation></ref><ref id="B14-nutrients-09-00325"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hong</surname><given-names>S.</given-names></name><name><surname>Lu</surname><given-names>Y.</given-names></name></person-group><article-title>Omega-3 fatty acid-derived resolvins and protectins in inflammation resolution and leukocyte functions: Targeting novel lipid mediator pathways in mitigation of acute kidney injury</article-title><source>Front. Immunol.</source><year>2013</year><volume>4</volume><fpage>13</fpage><pub-id pub-id-type="doi">10.3389/fimmu.2013.00013</pub-id><pub-id pub-id-type="pmid">23386851</pub-id></element-citation></ref><ref id="B15-nutrients-09-00325"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pullman-Mooar</surname><given-names>S.</given-names></name><name><surname>Laposata</surname><given-names>M.</given-names></name><name><surname>Lem</surname><given-names>D.</given-names></name><name><surname>Holman</surname><given-names>R.T.</given-names></name><name><surname>Leventhal</surname><given-names>L.J.</given-names></name><name><surname>DeMarco</surname><given-names>D.</given-names></name><name><surname>Zurier</surname><given-names>R.B.</given-names></name></person-group><article-title>Alteration of the cellular fatty acid profile and the production of eicosanoids in human monocytes by gamma-linolenic acid</article-title><source>Arthritis Rheum.</source><year>1990</year><volume>33</volume><fpage>1526</fpage><lpage>1533</lpage><pub-id pub-id-type="doi">10.1002/art.1780331010</pub-id><pub-id pub-id-type="pmid">2171540</pub-id></element-citation></ref><ref id="B16-nutrients-09-00325"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brzeski</surname><given-names>M.</given-names></name><name><surname>Madhok</surname><given-names>R.</given-names></name><name><surname>Capell</surname><given-names>H.A.</given-names></name></person-group><article-title>Evening primrose oil in patients with rheumatoid arthritis and side-effects of non-steroidal anti-inflammatory drugs</article-title><source>Br. J. Rheumatol.</source><year>1991</year><volume>30</volume><fpage>370</fpage><lpage>372</lpage><pub-id pub-id-type="doi">10.1093/rheumatology/30.5.370</pub-id><pub-id pub-id-type="pmid">1913008</pub-id></element-citation></ref><ref id="B17-nutrients-09-00325"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Leventhal</surname><given-names>L.J.</given-names></name><name><surname>Boyce</surname><given-names>E.G.</given-names></name><name><surname>Zurier</surname><given-names>R.B.</given-names></name></person-group><article-title>Treatment of rheumatoid arthritis with gammalinolenic acid</article-title><source>Ann. Intern. Med.</source><year>1993</year><volume>119</volume><fpage>867</fpage><lpage>873</lpage><pub-id pub-id-type="doi">10.7326/0003-4819-119-9-199311010-00001</pub-id><pub-id pub-id-type="pmid">8214997</pub-id></element-citation></ref><ref id="B18-nutrients-09-00325"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Leventhal</surname><given-names>L.J.</given-names></name><name><surname>Boyce</surname><given-names>E.G.</given-names></name><name><surname>Zurier</surname><given-names>R.B.</given-names></name></person-group><article-title>Treatment of rheumatoid arthritis with blackcurrant seed oil</article-title><source>Br. J. Rheumatol.</source><year>1994</year><volume>33</volume><fpage>847</fpage><lpage>852</lpage><pub-id pub-id-type="doi">10.1093/rheumatology/33.9.847</pub-id><pub-id pub-id-type="pmid">8081671</pub-id></element-citation></ref><ref id="B19-nutrients-09-00325"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zurier</surname><given-names>R.B.</given-names></name><name><surname>Rossetti</surname><given-names>R.G.</given-names></name><name><surname>Jacobson</surname><given-names>E.W.</given-names></name></person-group><article-title>Gamma-Linolenic acid treatment of rheumatoid arthritis. A randomized, placebo-controlled trial</article-title><source>Arthritis Rheum.</source><year>1996</year><volume>39</volume><fpage>1808</fpage><lpage>1817</lpage><pub-id pub-id-type="doi">10.1002/art.1780391106</pub-id><pub-id pub-id-type="pmid">8912502</pub-id></element-citation></ref><ref id="B20-nutrients-09-00325"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cameron</surname><given-names>M.</given-names></name><name><surname>Gagnier</surname><given-names>J.J.</given-names></name><name><surname>Little</surname><given-names>C.V.</given-names></name><name><surname>Parsons</surname><given-names>T.J.</given-names></name><name><surname>Blümle</surname><given-names>A.</given-names></name><name><surname>Chrubasik</surname><given-names>S.</given-names></name></person-group><article-title>Evidence of effectiveness of herbal medicinal products in the treatment of arthritis. Part 2: Rheumatoid arthritis</article-title><source>Phytother. Res.</source><year>2009</year><volume>23</volume><fpage>1647</fpage><lpage>1662</lpage><pub-id pub-id-type="doi">10.1002/ptr.3006</pub-id><pub-id pub-id-type="pmid">19941324</pub-id></element-citation></ref><ref id="B21-nutrients-09-00325"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aursnes</surname><given-names>M.</given-names></name><name><surname>Tungen</surname><given-names>J.E.</given-names></name><name><surname>Vik</surname><given-names>A.</given-names></name><name><surname>Colas</surname><given-names>R.</given-names></name><name><surname>Cheng</surname><given-names>C.Y.</given-names></name><name><surname>Dalli</surname><given-names>J.</given-names></name><name><surname>Serhan</surname><given-names>C.N.</given-names></name><name><surname>Hansen</surname><given-names>T.V.</given-names></name></person-group><article-title>Total synthesis of the lipid mediator PD1n-3 DPA: Configurational assignments and anti-inflammatory and pro-resolving actions</article-title><source>J. Nat. Prod.</source><year>2014</year><volume>77</volume><fpage>910</fpage><lpage>916</lpage><pub-id pub-id-type="doi">10.1021/np4009865</pub-id><pub-id pub-id-type="pmid">24576195</pub-id></element-citation></ref><ref id="B22-nutrients-09-00325"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Spite</surname><given-names>M.</given-names></name><name><surname>Clària</surname><given-names>J.</given-names></name><name><surname>Serhan</surname><given-names>C.N.</given-names></name></person-group><article-title>Resolvins, specialized proresolving lipid mediators, and their potential roles in metabolic diseases</article-title><source>Cell Metab.</source><year>2014</year><volume>19</volume><fpage>21</fpage><lpage>36</lpage><pub-id pub-id-type="doi">10.1016/j.cmet.2013.10.006</pub-id><pub-id pub-id-type="pmid">24239568</pub-id></element-citation></ref><ref id="B23-nutrients-09-00325"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Serhan</surname><given-names>C.N.</given-names></name><name><surname>Dalli</surname><given-names>J.</given-names></name><name><surname>Colas</surname><given-names>R.A.</given-names></name><name><surname>Winkler</surname><given-names>J.W.</given-names></name><name><surname>Chiang</surname><given-names>N.</given-names></name></person-group><article-title>Protectins and maresins: New pro-resolving families of mediators in acute inflammation and resolution bioactive metabolome</article-title><source>Biochim. Biophys. Acta</source><year>2015</year><volume>1851</volume><fpage>397</fpage><lpage>413</lpage><pub-id pub-id-type="doi">10.1016/j.bbalip.2014.08.006</pub-id><pub-id pub-id-type="pmid">25139562</pub-id></element-citation></ref><ref id="B24-nutrients-09-00325"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>C.</given-names></name><name><surname>Hume</surname><given-names>A.L.</given-names></name><name><surname>Krinsky</surname><given-names>D.L.</given-names></name></person-group><article-title>Fish oil supplements for rheumatoid arthritis: Some beneficial effects</article-title><source>Pharm. Today</source><year>2015</year><volume>21</volume><fpage>22</fpage><lpage>22</lpage><pub-id pub-id-type="doi">10.1016/S1042-0991(15)30441-2</pub-id></element-citation></ref><ref id="B25-nutrients-09-00325"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aletaha</surname><given-names>D.</given-names></name><name><surname>Neogi</surname><given-names>T.</given-names></name><name><surname>Silman</surname><given-names>A.J.</given-names></name><name><surname>Funovits</surname><given-names>J.</given-names></name><name><surname>Felson</surname><given-names>D.T.</given-names></name><name><surname>Bingham</surname><given-names>C.O.</given-names><suffix>3rd</suffix></name><name><surname>Birnbaum</surname><given-names>N.S.</given-names></name><name><surname>Burmester</surname><given-names>G.R.</given-names></name><name><surname>Bykerk</surname><given-names>V.P.</given-names></name><name><surname>Cohen</surname><given-names>M.D.</given-names></name><etal></etal></person-group><article-title>2010 Rheumatoid arthritis classification criteria: An American College of Rheumatology/European League against Rheumatism collaborative initiative</article-title><source>Arthritis Rheum.</source><year>2010</year><volume>62</volume><fpage>2569</fpage><lpage>2581</lpage><pub-id pub-id-type="doi">10.1002/art.27584</pub-id><pub-id pub-id-type="pmid">20872595</pub-id></element-citation></ref><ref id="B26-nutrients-09-00325"><label>26.</label><element-citation publication-type="web"><article-title>DAS 28 calculator V1.1-beta by Alfons and Michiel</article-title><comment>Available online: <ext-link ext-link-type="uri" xlink:href="http://www.umcn.nl.DAS28">http://www.umcn.nl.DAS28</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2016-03-05">(accessed on 5 March 2016)</date-in-citation></element-citation></ref><ref id="B27-nutrients-09-00325"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Petrović</surname><given-names>S.</given-names></name><name><surname>Takić</surname><given-names>M.</given-names></name><name><surname>Arsić</surname><given-names>A.</given-names></name><name><surname>Vučić</surname><given-names>V.</given-names></name><name><surname>Drakulić</surname><given-names>D.</given-names></name><name><surname>Milošević</surname><given-names>M.</given-names></name><name><surname>Glibetić</surname><given-names>M.</given-names></name></person-group><article-title>Effect of Sex Hormones on Plasma Phospholipid Fatty Acid Composition in Intact Rats and Rats with Bilaterally Occluded Carotid Arteries</article-title><source>Physiol. Res.</source><year>2014</year><volume>63</volume><fpage>331</fpage><lpage>339</lpage><pub-id pub-id-type="pmid">24564600</pub-id></element-citation></ref><ref id="B28-nutrients-09-00325"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Christopherson</surname><given-names>S.W.</given-names></name><name><surname>Glass</surname><given-names>R.L.</given-names></name></person-group><article-title>Preparation of milk methyl esters by alcoholysis in an essentially nonalcoholic solution</article-title><source>J. Daily Sci.</source><year>1969</year><volume>52</volume><fpage>1289</fpage><lpage>1290</lpage><pub-id pub-id-type="doi">10.3168/jds.S0022-0302(69)86739-1</pub-id></element-citation></ref><ref id="B29-nutrients-09-00325"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Arab</surname><given-names>L.</given-names></name><name><surname>Akbar</surname><given-names>J.</given-names></name></person-group><article-title>Biomarkers and the measurement of fatty acids</article-title><source>Public Health Nutr.</source><year>2002</year><volume>5</volume><fpage>865</fpage><lpage>871</lpage><pub-id pub-id-type="doi">10.1079/PHN2002391</pub-id><pub-id pub-id-type="pmid">12638594</pub-id></element-citation></ref><ref id="B30-nutrients-09-00325"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cvetković</surname><given-names>Z.</given-names></name><name><surname>Vučić</surname><given-names>V.</given-names></name><name><surname>Cvetković</surname><given-names>B.</given-names></name><name><surname>Petrović</surname><given-names>M.</given-names></name><name><surname>Ristić-Medić</surname><given-names>D.</given-names></name><name><surname>Tepšić</surname><given-names>J.</given-names></name><name><surname>Glibetić</surname><given-names>M.</given-names></name></person-group><article-title>Abnormal fatty acid distribution of the serum phospholipids of patients with non-Hodgkin lymphoma</article-title><source>Ann. Hematol.</source><year>2010</year><volume>89</volume><fpage>775</fpage><lpage>782</lpage><pub-id pub-id-type="doi">10.1007/s00277-010-0904-6</pub-id><pub-id pub-id-type="pmid">20127484</pub-id></element-citation></ref><ref id="B31-nutrients-09-00325"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ristic-Medic</surname><given-names>D.</given-names></name><name><surname>Takic</surname><given-names>M.</given-names></name><name><surname>Vucic</surname><given-names>V.</given-names></name><name><surname>Kostic</surname><given-names>N.</given-names></name><name><surname>Glibetic</surname><given-names>M.</given-names></name></person-group><article-title>Abnormalities in serum phospholipids fatty acid profile in patients with alcoholic liver currhosis- a pilot study</article-title><source>J. Clin. Biochem. Nutr.</source><year>2013</year><volume>53</volume><fpage>49</fpage><lpage>54</lpage><pub-id pub-id-type="doi">10.3164/jcbn.12-79</pub-id><pub-id pub-id-type="pmid">23874070</pub-id></element-citation></ref><ref id="B32-nutrients-09-00325"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Arsić</surname><given-names>A.</given-names></name><name><surname>Vučić</surname><given-names>V.</given-names></name><name><surname>Tepšić</surname><given-names>J.</given-names></name><name><surname>Mazić</surname><given-names>S.</given-names></name><name><surname>Djelić</surname><given-names>M.</given-names></name><name><surname>Glibetić</surname><given-names>M.</given-names></name></person-group><article-title>Altered plasma and erythrocyte phospholipid fatty acid profile in elite female water polo and football players</article-title><source>Appl. Physiol. Nutr. Metab.</source><year>2012</year><volume>37</volume><fpage>40</fpage><lpage>47</lpage><pub-id pub-id-type="doi">10.1139/h11-125</pub-id><pub-id pub-id-type="pmid">22165902</pub-id></element-citation></ref><ref id="B33-nutrients-09-00325"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tepsic</surname><given-names>J.</given-names></name><name><surname>Vucic</surname><given-names>V.</given-names></name><name><surname>Arsic</surname><given-names>A.</given-names></name><name><surname>Mazic</surname><given-names>S.</given-names></name><name><surname>Djelic</surname><given-names>M.</given-names></name><name><surname>Glibetic</surname><given-names>M.</given-names></name></person-group><article-title>Unfavourable plasma and erythrocyte phospholipid fatty acid profile in elite amateur boxers</article-title><source>Eur. J. Sport Sci.</source><year>2013</year><volume>13</volume><fpage>414</fpage><lpage>421</lpage><pub-id pub-id-type="doi">10.1080/17461391.2011.630105</pub-id><pub-id pub-id-type="pmid">23834548</pub-id></element-citation></ref><ref id="B34-nutrients-09-00325"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vučić</surname><given-names>V.</given-names></name></person-group><article-title>The role of dietary polyunsaturated fatty acids in inflammation</article-title><source>Serbian J. Exp. Clin. Res.</source><year>2013</year><volume>14</volume><fpage>93</fpage><lpage>99</lpage></element-citation></ref><ref id="B35-nutrients-09-00325"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Murphy</surname><given-names>R.A.</given-names></name><name><surname>Mourtzakis</surname><given-names>M.</given-names></name><name><surname>Chu</surname><given-names>Q.S.</given-names></name><name><surname>Baracos</surname><given-names>V.E.</given-names></name><name><surname>Reiman</surname><given-names>T.</given-names></name><name><surname>Mazurak</surname><given-names>V.C.</given-names></name></person-group><article-title>Supplementation with fish oil increases first-line chemotherapy efficacy in patients with advanced nonsmall cell lung cancer</article-title><source>Cancer</source><year>2011</year><volume>117</volume><fpage>3774</fpage><lpage>3780</lpage><pub-id pub-id-type="doi">10.1002/cncr.25933</pub-id><pub-id pub-id-type="pmid">21328326</pub-id></element-citation></ref><ref id="B36-nutrients-09-00325"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>C.</given-names></name><name><surname>Harris</surname><given-names>W.S.</given-names></name><name><surname>Chung</surname><given-names>M.</given-names></name><name><surname>Lichtenstein</surname><given-names>A.H.</given-names></name><name><surname>Balk</surname><given-names>E.M.</given-names></name><name><surname>Kupelnick</surname><given-names>B.</given-names></name><name><surname>Jordan</surname><given-names>H.S.</given-names></name><name><surname>Lau</surname><given-names>J.</given-names></name></person-group><article-title><italic>n</italic>-3 Fatty acids from fish or fishoil supplements, but not alpha-linolenic acid, benefit cardiovascular disease outcomes in primary- and secondary- prevention studies: A systematic review</article-title><source>Am. J. Clin. Nutr.</source><year>2006</year><volume>84</volume><fpage>5</fpage><lpage>17</lpage><pub-id pub-id-type="pmid">16825676</pub-id></element-citation></ref><ref id="B37-nutrients-09-00325"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Berbert</surname><given-names>A.A.</given-names></name><name><surname>Kondo</surname><given-names>C.R.</given-names></name><name><surname>Almendra</surname><given-names>C.L.</given-names></name><name><surname>Matsuo</surname><given-names>T.</given-names></name><name><surname>Dichi</surname><given-names>I.</given-names></name></person-group><article-title>Supplementation of fish oil and olive oil in patients with rheumatoid arthritis</article-title><source>Nutrition</source><year>2005</year><volume>21</volume><fpage>131</fpage><lpage>136</lpage><pub-id pub-id-type="doi">10.1016/j.nut.2004.03.023</pub-id><pub-id pub-id-type="pmid">15723739</pub-id></element-citation></ref><ref id="B38-nutrients-09-00325"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Das Gupta</surname><given-names>A.B.</given-names></name><name><surname>Hossain</surname><given-names>A.K.</given-names></name><name><surname>Islam</surname><given-names>M.H.</given-names></name><name><surname>Dey</surname><given-names>S.R.</given-names></name><name><surname>Khan</surname><given-names>A.L.</given-names></name></person-group><article-title>Role of omega-3 fatty acid supplementation with indomethacin in suppression of disease activity in rheumatoid arthritis</article-title><source>Bangladesh Med. Res. Counc. Bull.</source><year>2009</year><volume>35</volume><fpage>63</fpage><lpage>68</lpage><pub-id pub-id-type="pmid">20120782</pub-id></element-citation></ref><ref id="B39-nutrients-09-00325"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dawczynski</surname><given-names>C.</given-names></name><name><surname>Schubert</surname><given-names>R.</given-names></name><name><surname>Hein</surname><given-names>G.</given-names></name><name><surname>Müller</surname><given-names>A.</given-names></name><name><surname>Eidner</surname><given-names>T.</given-names></name><name><surname>Vogelsang</surname><given-names>H.</given-names></name><name><surname>Basu</surname><given-names>S.</given-names></name><name><surname>Jahreis</surname><given-names>G.</given-names></name></person-group><article-title>Long-term moderate intervention with <italic>n</italic>-3 long-chain PUFA supplemented dairy products: Effects on pathophysiological biomarkers in patients with rheumatoid arthritis</article-title><source>Br. J. Nutr.</source><year>2009</year><volume>101</volume><fpage>1517</fpage><lpage>1526</lpage><pub-id pub-id-type="doi">10.1017/S0007114508076216</pub-id><pub-id pub-id-type="pmid">19245735</pub-id></element-citation></ref><ref id="B40-nutrients-09-00325"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Calder</surname><given-names>P.C.</given-names></name></person-group><article-title>Marine omega-3 fatty acids and inflammatory processes: Effects, mechanisms and clinical relevance</article-title><source>Biochim. Biophys. Acta</source><year>2015</year><volume>1851</volume><fpage>469</fpage><lpage>484</lpage><pub-id pub-id-type="doi">10.1016/j.bbalip.2014.08.010</pub-id><pub-id pub-id-type="pmid">25149823</pub-id></element-citation></ref><ref id="B41-nutrients-09-00325"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>Y.H.</given-names></name><name><surname>Bae</surname><given-names>S.C.</given-names></name><name><surname>Song</surname><given-names>G.G.</given-names></name></person-group><article-title></article-title><source>Arch. Med. Res.</source><year>2012</year><volume>43</volume><fpage>356</fpage><lpage>362</lpage><pub-id pub-id-type="doi">10.1016/j.arcmed.2012.06.011</pub-id><pub-id pub-id-type="pmid">22835600</pub-id></element-citation></ref><ref id="B42-nutrients-09-00325"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barham</surname><given-names>J.B.</given-names></name><name><surname>Edens</surname><given-names>M.B.</given-names></name><name><surname>Fonteh</surname><given-names>A.N.</given-names></name><name><surname>Johnson</surname><given-names>M.M.</given-names></name><name><surname>Easter</surname><given-names>L.</given-names></name><name><surname>Chilton</surname><given-names>F.H.</given-names></name></person-group><article-title>Addition of eicosapentaenoic acid to gamma-linolenic acid supplemented diets prevents serum arachidonic acid accumulation in humans</article-title><source>J. Nutr.</source><year>2000</year><volume>130</volume><fpage>1925</fpage><lpage>1931</lpage><pub-id pub-id-type="pmid">10917903</pub-id></element-citation></ref><ref id="B43-nutrients-09-00325"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bhangle</surname><given-names>S.</given-names></name><name><surname>Kolasinski</surname><given-names>S.L.</given-names></name></person-group><article-title>Fish oil in rheumatic diseases</article-title><source>Rheum. Dis. Clin. N. Am.</source><year>2011</year><volume>37</volume><fpage>77</fpage><lpage>84</lpage><pub-id pub-id-type="doi">10.1016/j.rdc.2010.11.003</pub-id><pub-id pub-id-type="pmid">21220087</pub-id></element-citation></ref><ref id="B44-nutrients-09-00325"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Miles</surname><given-names>E.A.</given-names></name><name><surname>Calder</surname><given-names>P.C.</given-names></name></person-group><article-title>Influence of marine <italic>n</italic>-3 polyunsaturated fatty acids on immune function and a systematic review of their effects on clinical outcomes in rheumatoid arthritis</article-title><source>Br. J. Nutr.</source><year>2012</year><volume>107</volume><fpage>171</fpage><lpage>184</lpage><pub-id pub-id-type="doi">10.1017/S0007114512001560</pub-id><pub-id pub-id-type="pmid">22591891</pub-id></element-citation></ref><ref id="B45-nutrients-09-00325"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rajaei</surname><given-names>E.</given-names></name><name><surname>Mowla</surname><given-names>K.</given-names></name><name><surname>Ghorbani</surname><given-names>A.</given-names></name><name><surname>Bahadoram</surname><given-names>S.</given-names></name><name><surname>Bahadoram</surname><given-names>M.</given-names></name><name><surname>Dargahi-Malamir</surname><given-names>M.</given-names></name></person-group><article-title>The Effect of Omega-3 Fatty Acids in Patients With Active Rheumatoid Arthritis Receiving DMARDs Therapy: Double-Blind Randomized Controlled Trial</article-title><source>Glob. J. Health Sci.</source><year>2015</year><volume>8</volume><fpage>18</fpage><lpage>25</lpage><pub-id pub-id-type="doi">10.5539/gjhs.v8n7p18</pub-id><pub-id pub-id-type="pmid">26925896</pub-id></element-citation></ref><ref id="B46-nutrients-09-00325"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Olendzki</surname><given-names>B.C.</given-names></name><name><surname>Leung</surname><given-names>K.</given-names></name><name><surname>Van Buskirk</surname><given-names>S.</given-names></name><name><surname>Reed</surname><given-names>G.</given-names></name><name><surname>Zurier</surname><given-names>R.B.</given-names></name></person-group><article-title>Treatment of rheumatoid arthritiswith marine and botanical oils: Influence on serum lipids</article-title><source>Evid. Based Complement. Altern. Med.</source><year>2011</year><volume>2011</volume><fpage>8272</fpage><lpage>8286</lpage><pub-id pub-id-type="doi">10.1155/2011/827286</pub-id><pub-id pub-id-type="pmid">22007257</pub-id></element-citation></ref><ref id="B47-nutrients-09-00325"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Klein</surname><given-names>K.</given-names></name><name><surname>Gay</surname><given-names>S.</given-names></name></person-group><article-title>Epigenetics in rheumatoid arthritis</article-title><source>Curr. Opin. Rheumatol.</source><year>2015</year><volume>27</volume><fpage>76</fpage><lpage>82</lpage><pub-id pub-id-type="doi">10.1097/BOR.0000000000000128</pub-id><pub-id pub-id-type="pmid">25415526</pub-id></element-citation></ref><ref id="B48-nutrients-09-00325"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fenton</surname><given-names>J.I.</given-names></name><name><surname>Hord</surname><given-names>N.G.</given-names></name><name><surname>Ghosh</surname><given-names>S.</given-names></name><name><surname>Gurzell</surname><given-names>E.A.</given-names></name></person-group><article-title>Immunomodulation by dietary long chain omega-3 fatty acids and the potential for adverse health outcomes</article-title><source>Prostaglandins Leukot. Essent. Fatty Acids</source><year>2013</year><volume>89</volume><fpage>379</fpage><lpage>390</lpage><pub-id pub-id-type="doi">10.1016/j.plefa.2013.09.011</pub-id><pub-id pub-id-type="pmid">24183073</pub-id></element-citation></ref><ref id="B49-nutrients-09-00325"><label>49.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sandoo</surname><given-names>A.</given-names></name><name><surname>Veldhuijzen van Zanten</surname><given-names>J.J.</given-names></name><name><surname>Metsios</surname><given-names>G.S.</given-names></name><name><surname>Carroll</surname><given-names>D.</given-names></name><name><surname>Kitas</surname><given-names>G.D.</given-names></name></person-group><article-title>Vascular function and morphology in rheumatoid arthritis: A systematic review</article-title><source>Rheumatology (Oxf.)</source><year>2011</year><volume>50</volume><fpage>2125</fpage><lpage>2139</lpage><pub-id pub-id-type="doi">10.1093/rheumatology/ker275</pub-id><pub-id pub-id-type="pmid">21926155</pub-id></element-citation></ref><ref id="B50-nutrients-09-00325"><label>50.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Harris</surname><given-names>W.S.</given-names></name><name><surname>Von Schacky</surname><given-names>C.</given-names></name></person-group><article-title>The Omega-3 Index: A new risk factor for death from coronary heart disease?</article-title><source>Prev. Med.</source><year>2004</year><volume>39</volume><fpage>212</fpage><lpage>220</lpage><pub-id pub-id-type="doi">10.1016/j.ypmed.2004.02.030</pub-id><pub-id pub-id-type="pmid">15208005</pub-id></element-citation></ref><ref id="B51-nutrients-09-00325"><label>51.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jabbar</surname><given-names>R.</given-names></name><name><surname>Saldeen</surname><given-names>T.</given-names></name></person-group><article-title>A new predictor of risk for sudden cardiac death</article-title><source>Ups. J. Med. Sci.</source><year>2006</year><volume>111</volume><fpage>169</fpage><lpage>177</lpage><pub-id pub-id-type="doi">10.3109/2000-1967-033</pub-id><pub-id pub-id-type="pmid">16961172</pub-id></element-citation></ref><ref id="B52-nutrients-09-00325"><label>52.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dawczynski</surname><given-names>C.</given-names></name><name><surname>Hackermeier</surname><given-names>U.</given-names></name><name><surname>Viehweger</surname><given-names>M.</given-names></name><name><surname>Stange</surname><given-names>R.</given-names></name><name><surname>Springer</surname><given-names>M.</given-names></name><name><surname>Jahreis</surname><given-names>G.</given-names></name></person-group><article-title>Incorporation of <italic>n</italic>-3 PUFA and γ-linolenic acid in blood lipids and red blood cell lipids together with their influence on disease activity in patients with chronic inflammatory arthritis—A randomized controlled human intervention trial</article-title><source>Lipids Health Dis.</source><year>2011</year><volume>10</volume><fpage>130</fpage><pub-id pub-id-type="doi">10.1186/1476-511X-10-130</pub-id><pub-id pub-id-type="pmid">21816071</pub-id></element-citation></ref><ref id="B53-nutrients-09-00325"><label>53.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aviña-Zubieta</surname><given-names>J.A.</given-names></name><name><surname>Choi</surname><given-names>H.K.</given-names></name><name><surname>Sadatsafavi</surname><given-names>M.</given-names></name><name><surname>Etminan</surname><given-names>M.</given-names></name><name><surname>Esdaile</surname><given-names>J.M.</given-names></name><name><surname>Lacaille</surname><given-names>D.</given-names></name></person-group><article-title>Risk of cardiovascular mortality in patients with rheumatoid arthritis: A meta-analysis of observational studies</article-title><source>Arthritis Rheum.</source><year>2008</year><volume>59</volume><fpage>1690</fpage><lpage>1697</lpage><pub-id pub-id-type="doi">10.1002/art.24092</pub-id><pub-id pub-id-type="pmid">19035419</pub-id></element-citation></ref><ref id="B54-nutrients-09-00325"><label>54.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Meune</surname><given-names>C.</given-names></name><name><surname>Touzé</surname><given-names>E.</given-names></name><name><surname>Trinquart</surname><given-names>L.</given-names></name><name><surname>Allanore</surname><given-names>Y.</given-names></name></person-group><article-title>Trends in cardiovascular mortality in patients with rheumatoid arthritis over 50 years: A systematic review and meta-analysis of cohort studies</article-title><source>Rheumatology (Oxf.)</source><year>2009</year><volume>48</volume><fpage>1309</fpage><lpage>1313</lpage><pub-id pub-id-type="doi">10.1093/rheumatology/kep252</pub-id><pub-id pub-id-type="pmid">19696061</pub-id></element-citation></ref></ref-list></back><floats-group><table-wrap id="nutrients-09-00325-t001" orientation="portrait" position="float"><object-id pub-id-type="pii">nutrients-09-00325-t001_Table 1</object-id><label>Table 1</label><caption><p>Baseline characteristics of the patients with rheumatoid arthritis.</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" colspan="1">Patients’ Characteristics</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Group I</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Group II</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Group III</th><th rowspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" colspan="1"><italic>p</italic> Value</th></tr><tr><th align="center" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic>n</italic> = 20</th><th align="center" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic>n</italic> = 20</th><th align="center" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic>n</italic> = 20</th></tr></thead><tbody><tr><td align="center" valign="top" rowspan="1" colspan="1">Age (X ± SD; years)</td><td align="center" valign="top" rowspan="1" colspan="1">54 ± 8</td><td align="center" valign="top" rowspan="1" colspan="1">57 ± 8</td><td align="center" valign="top" rowspan="1" colspan="1">59 ± 7</td><td align="center" valign="top" rowspan="1" colspan="1">NS</td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1">BMI (kg/m<sup>2</sup>)</td><td align="center" valign="top" rowspan="1" colspan="1">26.48 ± 4.15</td><td align="center" valign="top" rowspan="1" colspan="1">26.52 ± 4.37</td><td align="center" valign="top" rowspan="1" colspan="1">24.65 ± 6.29</td><td align="center" valign="top" rowspan="1" colspan="1">NS</td></tr><tr><td align="center" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">Disease duration</td><td align="center" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">6.6 ± 4.0</td><td align="center" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">8.1 ± 2.7</td><td align="center" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">7.2 ± 2.6</td><td align="center" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">NS</td></tr></tbody></table><table-wrap-foot><fn><p>Values are expressed as mean ± SD; BMI: body mass index; NS: not statistically significant, assessed by one-way ANOVA.</p></fn></table-wrap-foot></table-wrap><table-wrap id="nutrients-09-00325-t002" orientation="portrait" position="float"><object-id pub-id-type="pii">nutrients-09-00325-t002_Table 2</object-id><label>Table 2</label><caption><p>Comparisons of clinical and laboratory results in patients at the start and the end of the supplementation.</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" colspan="1">Patients’ Characteristics</th><th rowspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" colspan="1">Timing</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Group I</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Group II</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Group III</th></tr><tr><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic>n</italic> = 20</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic>n</italic> = 20</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic>n</italic> = 20</th></tr></thead><tbody><tr><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">CRP (mg/L)</td><td align="center" valign="middle" rowspan="1" colspan="1">Baseline</td><td align="center" valign="middle" rowspan="1" colspan="1">12.4 ± 8.2</td><td align="center" valign="middle" rowspan="1" colspan="1">16.0 ± 18.3</td><td align="center" valign="middle" rowspan="1" colspan="1">12.7 ± 7.2</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">End of study</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">7.3 ± 2.9 ***</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">7.1 ± 5.5 ***</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">6.9 ± 3.5 ***</td></tr><tr><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Tender joint count</td><td align="center" valign="middle" rowspan="1" colspan="1">Baseline</td><td align="center" valign="middle" rowspan="1" colspan="1">6.2 ± 2.0</td><td align="center" valign="middle" rowspan="1" colspan="1">5.4 ± 1.9</td><td align="center" valign="middle" rowspan="1" colspan="1">5.0 ± 2.0</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">End of study</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3.3 ± 1.5 ***</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4.0 ± 1.4 ***</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4.6 ± 1.6</td></tr><tr><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Swollen joint count</td><td align="center" valign="middle" rowspan="1" colspan="1">Baseline</td><td align="center" valign="middle" rowspan="1" colspan="1">1.8 ± 1.0</td><td align="center" valign="middle" rowspan="1" colspan="1">1.5 ± 1.6</td><td align="center" valign="middle" rowspan="1" colspan="1">1.0 ± 1.3</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">End of study</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.8 ± 0.3 ***</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.3 ± 0.8 ***</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.4 ± 0.2 **</td></tr><tr><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">VAS (pain)</td><td align="center" valign="middle" rowspan="1" colspan="1">Baseline</td><td align="center" valign="middle" rowspan="1" colspan="1">55.7 ± 10.1</td><td align="center" valign="middle" rowspan="1" colspan="1">59.0 ± 9.1</td><td align="center" valign="middle" rowspan="1" colspan="1">61.5 ± 8.9</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">End of study</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">46.7 ± 7.1 ***</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">50.5 ± 7.0 ***</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">59.3 ± 6.9</td></tr><tr><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">ESR, mm/h</td><td align="center" valign="middle" rowspan="1" colspan="1">Baseline</td><td align="center" valign="middle" rowspan="1" colspan="1">35.0 ± 24.1</td><td align="center" valign="middle" rowspan="1" colspan="1">36.7 ± 19.2</td><td align="center" valign="middle" rowspan="1" colspan="1">33.3 ± 17.1</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">End of study</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">23.2 ± 16.6 ***</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">19.9 ± 10.8 ***</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">24.1 ± 13.9 **</td></tr><tr><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">DAS 28</td><td align="center" valign="middle" rowspan="1" colspan="1">Baseline</td><td align="center" valign="middle" rowspan="1" colspan="1">4.99 ± 0.88</td><td align="center" valign="middle" rowspan="1" colspan="1">4.76 ± 0.85</td><td align="center" valign="middle" rowspan="1" colspan="1">4.66 ± 0.80</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">End of study</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3.91 ± 0.80 ***</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3.79 ± 0.72 ***</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4.23 ± 0.66</td></tr></tbody></table><table-wrap-foot><fn><p>** Significantly different compared to the start value (<italic>p</italic> ≤ 0.01); *** (<italic>p</italic> ≤ 0.001). Values are expressed as mean ± SD; CRP: C-reactive protein; VAS: visual analogue scale; ESR: erythrocyte sedimentation rate; DAS 28: disease activity score 28. </p></fn></table-wrap-foot></table-wrap><table-wrap id="nutrients-09-00325-t003" orientation="portrait" position="float"><object-id pub-id-type="pii">nutrients-09-00325-t003_Table 3</object-id><label>Table 3</label><caption><p>Fatty acid distribution in plasma phospholipids at baseline and after a 12-week intake of five <italic>Omega</italic>-<italic>3 Cardio</italic> gel capsules daily.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Fatty Acid Distribution</th><th colspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1">Group I</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Statistical Significance</th></tr></thead><tbody><tr><td align="center" valign="top" rowspan="1" colspan="1">Fatty acid</td><td align="center" valign="top" rowspan="1" colspan="1">Baseline</td><td align="center" valign="top" rowspan="1" colspan="1">After 12 wk</td><td align="center" valign="top" rowspan="1" colspan="1"><italic>p</italic> value</td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1">16:0</td><td align="center" valign="top" rowspan="1" colspan="1">30.07 ± 5.22</td><td align="center" valign="top" rowspan="1" colspan="1">29.47 ± 2.31</td><td align="center" valign="top" rowspan="1" colspan="1">NS</td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1">16:1 <italic>n</italic>-7</td><td align="center" valign="top" rowspan="1" colspan="1">0.57 ± 0.15</td><td align="center" valign="top" rowspan="1" colspan="1">0.53 ± 0.23</td><td align="center" valign="top" rowspan="1" colspan="1">NS</td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1">18:0</td><td align="center" valign="top" rowspan="1" colspan="1">18.59 ± 2.82</td><td align="center" valign="top" rowspan="1" colspan="1">16.77 ± 2.53</td><td align="center" valign="top" rowspan="1" colspan="1">NS</td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1">18:1 <italic>n</italic>-9</td><td align="center" valign="top" rowspan="1" colspan="1">9.32 ± 1.24</td><td align="center" valign="top" rowspan="1" colspan="1">8.05 ± 1.05</td><td align="center" valign="top" rowspan="1" colspan="1">NS</td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1">18:1 <italic>n</italic>-7</td><td align="center" valign="top" rowspan="1" colspan="1">1.99 ± 0.33</td><td align="center" valign="top" rowspan="1" colspan="1">1.58 ± 0.25</td><td align="center" valign="top" rowspan="1" colspan="1">0.010</td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1">18:2 <italic>n</italic>-6LA</td><td align="center" valign="top" rowspan="1" colspan="1">23.73 ± 2.43</td><td align="center" valign="top" rowspan="1" colspan="1">26.03 ± 2.91</td><td align="center" valign="top" rowspan="1" colspan="1">NS</td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1">18:3 <italic>n</italic>-3ALA</td><td align="center" valign="top" rowspan="1" colspan="1">0.23 ± 0.24</td><td align="center" valign="top" rowspan="1" colspan="1">0.21 ± 0.13</td><td align="center" valign="top" rowspan="1" colspan="1">NS</td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1">18:3 <italic>n</italic>-6GLA</td><td align="center" valign="top" rowspan="1" colspan="1">0.00 ± 0.00</td><td align="center" valign="top" rowspan="1" colspan="1">0.00 ± 0.00</td><td align="center" valign="top" rowspan="1" colspan="1">NS</td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1">20:3 <italic>n</italic>-6DGLA</td><td align="center" valign="top" rowspan="1" colspan="1">2.84 ± 0.80</td><td align="center" valign="top" rowspan="1" colspan="1">2.46 ± 0.94</td><td align="center" valign="top" rowspan="1" colspan="1">NS</td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1">20:4 <italic>n</italic>-6AA</td><td align="center" valign="top" rowspan="1" colspan="1">11.05 ± 3.31</td><td align="center" valign="top" rowspan="1" colspan="1">10.22 ± 1.81</td><td align="center" valign="top" rowspan="1" colspan="1">NS</td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1">20:5 <italic>n</italic>-3EPA</td><td align="center" valign="top" rowspan="1" colspan="1">0.32 ± 0.22</td><td align="center" valign="top" rowspan="1" colspan="1">1.01 ± 1.02</td><td align="center" valign="top" rowspan="1" colspan="1">0.026</td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1">22:4 <italic>n</italic>-6</td><td align="center" valign="top" rowspan="1" colspan="1">0.45 ± 0.38</td><td align="center" valign="top" rowspan="1" colspan="1">0.32 ± 0.13</td><td align="center" valign="top" rowspan="1" colspan="1">NS</td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1">22:5 <italic>n</italic>-3DPA</td><td align="center" valign="top" rowspan="1" colspan="1">0.38 ± 0.17</td><td align="center" valign="top" rowspan="1" colspan="1">0.58 ± 0.30</td><td align="center" valign="top" rowspan="1" colspan="1">NS</td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1">22:6 <italic>n</italic>-3DHA</td><td align="center" valign="top" rowspan="1" colspan="1">1.92 ± 0.91</td><td align="center" valign="top" rowspan="1" colspan="1">2.74 ± 1.08</td><td align="center" valign="top" rowspan="1" colspan="1">0.007</td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1"><italic>n</italic>-3</td><td align="center" valign="top" rowspan="1" colspan="1">2.85 ± 1.14</td><td align="center" valign="top" rowspan="1" colspan="1">4.55 ± 2.26</td><td align="center" valign="top" rowspan="1" colspan="1">0.013</td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1"><italic>n</italic>-6</td><td align="center" valign="top" rowspan="1" colspan="1">38.08 ± 3.80</td><td align="center" valign="top" rowspan="1" colspan="1">39.05 ± 3.22</td><td align="center" valign="top" rowspan="1" colspan="1">NS</td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1"><italic>n</italic>-6/<italic>n</italic>-3</td><td align="center" valign="top" rowspan="1" colspan="1">15.47 ± 5.51</td><td align="center" valign="top" rowspan="1" colspan="1">10.62 ± 5.07</td><td align="center" valign="top" rowspan="1" colspan="1">0.005</td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1">SFA</td><td align="center" valign="top" rowspan="1" colspan="1">47.17 ± 3.59</td><td align="center" valign="top" rowspan="1" colspan="1">46.24 ± 3.97</td><td align="center" valign="top" rowspan="1" colspan="1">NS</td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1">MUFA</td><td align="center" valign="top" rowspan="1" colspan="1">11.89 ± 1.33</td><td align="center" valign="top" rowspan="1" colspan="1">10.16 ± 1.34</td><td align="center" valign="top" rowspan="1" colspan="1">0.012</td></tr><tr><td align="center" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">PUFA</td><td align="center" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">40.61 ± 3.52</td><td align="center" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">43.13 ± 3.17</td><td align="center" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">0.013</td></tr></tbody></table><table-wrap-foot><fn><p>Data are expressed as the mean ± SD; NS: not statistically significant; LA: linoleic acid; GLA: ɤ-linolenic acid; ALA: α-linolenic acid; DGLA: dihomo-ɤ-linolenic acid; AA: arachidonic acid; EPA: eicosapentaenoic acid; DPA: docosapentaenoic acid; DHA: docosahexaenoic acid; SFA: saturated fatty acids; MUFA: monounsaturated fatty acids; PUFA: polyunsaturated fatty acids.</p></fn></table-wrap-foot></table-wrap><table-wrap id="nutrients-09-00325-t004" orientation="portrait" position="float"><object-id pub-id-type="pii">nutrients-09-00325-t004_Table 4</object-id><label>Table 4</label><caption><p>Fatty acid distribution in plasma phospholipids at baseline and after a 12-week intake of two <italic>Omega</italic>-<italic>3 Cardio</italic> gel capsules and two <italic>Evening Primrose Oil</italic> gel capsules daily.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="top" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Fatty Acid Distribution</th><th colspan="2" align="center" valign="top" style="border-top:solid thin;border-bottom:solid thin" rowspan="1">Group II</th><th align="center" valign="top" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Statistical Significance</th></tr></thead><tbody><tr><td align="center" valign="top" rowspan="1" colspan="1">Fatty acid</td><td align="center" valign="top" rowspan="1" colspan="1">Baseline</td><td align="center" valign="top" rowspan="1" colspan="1">After 12 week</td><td align="center" valign="top" rowspan="1" colspan="1"><italic>p</italic> value</td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1">16:0</td><td align="center" valign="top" rowspan="1" colspan="1">30.08 ± 5.06</td><td align="center" valign="top" rowspan="1" colspan="1">28.85 ± 2.62</td><td align="center" valign="top" rowspan="1" colspan="1">NS</td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1">16:1 <italic>n</italic>-7</td><td align="center" valign="top" rowspan="1" colspan="1">0.56 ± 0.13</td><td align="center" valign="top" rowspan="1" colspan="1">0.58 ± 0.26</td><td align="center" valign="top" rowspan="1" colspan="1">NS</td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1">18:0</td><td align="center" valign="top" rowspan="1" colspan="1">16.93 ± 1.83</td><td align="center" valign="top" rowspan="1" colspan="1">16.34 ± 1.41</td><td align="center" valign="top" rowspan="1" colspan="1">NS</td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1">18:1 <italic>n</italic>-9</td><td align="center" valign="top" rowspan="1" colspan="1">8.64 ± 1.03</td><td align="center" valign="top" rowspan="1" colspan="1"> 8.44 ± 0.93</td><td align="center" valign="top" rowspan="1" colspan="1">NS</td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1">18:1 <italic>n</italic>-7</td><td align="center" valign="top" rowspan="1" colspan="1">1.75 ± 0.24</td><td align="center" valign="top" rowspan="1" colspan="1">1.63 ± 0.23</td><td align="center" valign="top" rowspan="1" colspan="1">NS</td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1">18:2 <italic>n</italic>-6LA</td><td align="center" valign="top" rowspan="1" colspan="1">26.20 ± 1.90</td><td align="center" valign="top" rowspan="1" colspan="1">26.30 ± 2.41</td><td align="center" valign="top" rowspan="1" colspan="1">NS</td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1">18:3 <italic>n</italic>-3ALA</td><td align="center" valign="top" rowspan="1" colspan="1">0.22 ± 0.18</td><td align="center" valign="top" rowspan="1" colspan="1">0.18 ± 0.15</td><td align="center" valign="top" rowspan="1" colspan="1">NS</td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1">18:3 <italic>n</italic>-6GLA</td><td align="center" valign="top" rowspan="1" colspan="1">0.00 ± 0.00</td><td align="center" valign="top" rowspan="1" colspan="1">0.13 ± 0.11</td><td align="center" valign="top" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1">20:3 <italic>n</italic>-6DGLA</td><td align="center" valign="top" rowspan="1" colspan="1">2.59 ± 0.63</td><td align="center" valign="top" rowspan="1" colspan="1">2.67 ± 0.63</td><td align="center" valign="top" rowspan="1" colspan="1">NS</td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1">20:4 <italic>n</italic>-6AA</td><td align="center" valign="top" rowspan="1" colspan="1">10.52 ± 1.81</td><td align="center" valign="top" rowspan="1" colspan="1">11.29 ± 2.14</td><td align="center" valign="top" rowspan="1" colspan="1"><italic>p</italic> = 0.048</td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1">20:5 <italic>n</italic>-3EPA</td><td align="center" valign="top" rowspan="1" colspan="1">0.20 ± 0.10</td><td align="center" valign="top" rowspan="1" colspan="1">0.49 ± 0.23</td><td align="center" valign="top" rowspan="1" colspan="1"><italic>p</italic> &lt; 0.001</td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1">22:4 <italic>n</italic>-6</td><td align="center" valign="top" rowspan="1" colspan="1">0.37 ± 0.18</td><td align="center" valign="top" rowspan="1" colspan="1">0.34 ± 0.13</td><td align="center" valign="top" rowspan="1" colspan="1">NS</td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1">22:5 <italic>n</italic>-3DPA</td><td align="center" valign="top" rowspan="1" colspan="1">0.31 ± 0.08</td><td align="center" valign="top" rowspan="1" colspan="1">0.45 ± 0.16</td><td align="center" valign="top" rowspan="1" colspan="1"><italic>p</italic> &lt; 0.001</td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1">22:6 <italic>n</italic>-3DHA</td><td align="center" valign="top" rowspan="1" colspan="1">1.61 ± 0.55</td><td align="center" valign="top" rowspan="1" colspan="1">2.22 ± 0.74</td><td align="center" valign="top" rowspan="1" colspan="1"><italic>p</italic> = 0.006</td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1"><italic>n</italic>-3</td><td align="center" valign="top" rowspan="1" colspan="1">2.34 ± 0.65</td><td align="center" valign="top" rowspan="1" colspan="1">3.33 ± 1.00</td><td align="center" valign="top" rowspan="1" colspan="1"><italic>p</italic> = 0.001</td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1"><italic>n</italic>-6</td><td align="center" valign="top" rowspan="1" colspan="1">39.69 ± 3.08</td><td align="center" valign="top" rowspan="1" colspan="1">40.75 ± 2.86</td><td align="center" valign="top" rowspan="1" colspan="1">NS</td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1"><italic>n</italic>-6/<italic>n</italic>-3</td><td align="center" valign="top" rowspan="1" colspan="1">18.15 ± 5.04</td><td align="center" valign="top" rowspan="1" colspan="1">13.50 ± 4.81</td><td align="center" valign="top" rowspan="1" colspan="1"><italic>p</italic> = 0.005</td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1">SFA</td><td align="center" valign="top" rowspan="1" colspan="1">47.01 ± 3.62</td><td align="center" valign="top" rowspan="1" colspan="1">45.19 ± 2.80</td><td align="center" valign="top" rowspan="1" colspan="1"><italic>p</italic> = 0.039</td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1">MUFA</td><td align="center" valign="top" rowspan="1" colspan="1">10.56 ± 1.46</td><td align="center" valign="top" rowspan="1" colspan="1">10.67 ± 1.12</td><td align="center" valign="top" rowspan="1" colspan="1">NS</td></tr><tr><td align="center" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">PUFA</td><td align="center" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">42.04 ± 3.38</td><td align="center" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">44.07 ± 2.96</td><td align="center" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic>p</italic> = 0.020</td></tr></tbody></table><table-wrap-foot><fn><p>Data are expressed as the mean ± SD; NS: not statistically significant; Abbreviations as in <xref ref-type="table" rid="nutrients-09-00325-t003">Table 3</xref>.</p></fn></table-wrap-foot></table-wrap><table-wrap id="nutrients-09-00325-t005" orientation="portrait" position="float"><object-id pub-id-type="pii">nutrients-09-00325-t005_Table 5</object-id><label>Table 5</label><caption><p>Fatty acid distribution in plasma phospholipids at baseline and after 12 weeks without supplementation.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="top" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Fatty Acid Distribution</th><th colspan="2" align="center" valign="top" style="border-top:solid thin;border-bottom:solid thin" rowspan="1">Group III</th><th align="center" valign="top" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Statistical Significance</th></tr></thead><tbody><tr><td align="center" valign="top" rowspan="1" colspan="1">Fatty acid</td><td align="center" valign="top" rowspan="1" colspan="1">Baseline</td><td align="center" valign="top" rowspan="1" colspan="1">After 12 wk</td><td align="center" valign="top" rowspan="1" colspan="1"><italic>p</italic> value</td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1">16:0</td><td align="center" valign="top" rowspan="1" colspan="1">32.21 ± 3.69</td><td align="center" valign="top" rowspan="1" colspan="1">29.67 ± 3.88</td><td align="center" valign="top" rowspan="1" colspan="1">NS</td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1">16:1 <italic>n</italic>-7</td><td align="center" valign="top" rowspan="1" colspan="1">0.72 ± 0.61</td><td align="center" valign="top" rowspan="1" colspan="1">0.57 ± 0.12</td><td align="center" valign="top" rowspan="1" colspan="1">NS</td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1">18:0</td><td align="center" valign="top" rowspan="1" colspan="1">16.19 ± 2.40</td><td align="center" valign="top" rowspan="1" colspan="1">16.55 ± 1.82</td><td align="center" valign="top" rowspan="1" colspan="1">NS</td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1">18:1 <italic>n</italic>-9</td><td align="center" valign="top" rowspan="1" colspan="1">8.51 ± 1.45</td><td align="center" valign="top" rowspan="1" colspan="1">8.35 ± 1.39</td><td align="center" valign="top" rowspan="1" colspan="1">NS</td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1">18:1 <italic>n</italic>-7</td><td align="center" valign="top" rowspan="1" colspan="1">1.69 ± 0.25</td><td align="center" valign="top" rowspan="1" colspan="1">1.68 ± 0.30</td><td align="center" valign="top" rowspan="1" colspan="1">NS</td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1">18:2 <italic>n</italic>-6LA</td><td align="center" valign="top" rowspan="1" colspan="1">26.40 ± 3.47</td><td align="center" valign="top" rowspan="1" colspan="1">27.49 ± 3.96</td><td align="center" valign="top" rowspan="1" colspan="1">NS</td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1">18:3 <italic>n</italic>-3ALA</td><td align="center" valign="top" rowspan="1" colspan="1">0.21 ± 0.14</td><td align="center" valign="top" rowspan="1" colspan="1">0.19 ± 0.23</td><td align="center" valign="top" rowspan="1" colspan="1">NS</td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1">18:3 <italic>n</italic>-6GLA</td><td align="center" valign="top" rowspan="1" colspan="1">0.00 ± 0.00</td><td align="center" valign="top" rowspan="1" colspan="1">0.00 ± 0.00</td><td align="center" valign="top" rowspan="1" colspan="1">NS</td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1">20:3 <italic>n</italic>-6DGLA</td><td align="center" valign="top" rowspan="1" colspan="1">2.44 ± 0.78</td><td align="center" valign="top" rowspan="1" colspan="1">2.82 ± 0.97</td><td align="center" valign="top" rowspan="1" colspan="1">NS</td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1">20:4 <italic>n</italic>-6AA</td><td align="center" valign="top" rowspan="1" colspan="1">8.98 ± 1.84</td><td align="center" valign="top" rowspan="1" colspan="1">9.60 ± 2.90</td><td align="center" valign="top" rowspan="1" colspan="1">NS</td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1">20:5 <italic>n</italic>-3EPA</td><td align="center" valign="top" rowspan="1" colspan="1">0.29 ± 0.18</td><td align="center" valign="top" rowspan="1" colspan="1">0.34 ± 0.16</td><td align="center" valign="top" rowspan="1" colspan="1">NS</td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1">22:4 <italic>n</italic>-6</td><td align="center" valign="top" rowspan="1" colspan="1">0.32 ± 0.14</td><td align="center" valign="top" rowspan="1" colspan="1">0.29 ± 0.13</td><td align="center" valign="top" rowspan="1" colspan="1">NS</td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1">22:5 <italic>n</italic>-3DPA</td><td align="center" valign="top" rowspan="1" colspan="1">0.32 ± 0.14</td><td align="center" valign="top" rowspan="1" colspan="1">0.56 ± 0.69</td><td align="center" valign="top" rowspan="1" colspan="1">NS</td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1">22:6 <italic>n</italic>-3DHA</td><td align="center" valign="top" rowspan="1" colspan="1">1.66 ± 0.69</td><td align="center" valign="top" rowspan="1" colspan="1">1.83 ± 0.72</td><td align="center" valign="top" rowspan="1" colspan="1">NS</td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1"><italic>n</italic>-3</td><td align="center" valign="top" rowspan="1" colspan="1">2.46 ± 0.90</td><td align="center" valign="top" rowspan="1" colspan="1">2.66 ± 0.81</td><td align="center" valign="top" rowspan="1" colspan="1">NS</td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1"><italic>n</italic>-6</td><td align="center" valign="top" rowspan="1" colspan="1">38.14 ± 3.09</td><td align="center" valign="top" rowspan="1" colspan="1">40.03 ± 2.71</td><td align="center" valign="top" rowspan="1" colspan="1">NS</td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1"><italic>n</italic>-6/<italic>n</italic>-3</td><td align="center" valign="top" rowspan="1" colspan="1">17.25 ± 5.51</td><td align="center" valign="top" rowspan="1" colspan="1">16.24 ± 3.14</td><td align="center" valign="top" rowspan="1" colspan="1">NS</td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1">SFA</td><td align="center" valign="top" rowspan="1" colspan="1">48.41 ± 3.02</td><td align="center" valign="top" rowspan="1" colspan="1">46.26 ± 3.67</td><td align="center" valign="top" rowspan="1" colspan="1">NS</td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1">MUFA</td><td align="center" valign="top" rowspan="1" colspan="1">9.72 ± 2.41</td><td align="center" valign="top" rowspan="1" colspan="1">10.61 ± 1.74</td><td align="center" valign="top" rowspan="1" colspan="1">NS</td></tr><tr><td align="center" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">PUFA</td><td align="center" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">40.49 ± 4.45</td><td align="center" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">43.60 ± 4.22</td><td align="center" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">NS</td></tr></tbody></table><table-wrap-foot><fn><p>Data are expressed as the mean ± SD; Abbreviations as in <xref ref-type="table" rid="nutrients-09-00325-t003">Table 3</xref>.</p></fn></table-wrap-foot></table-wrap><table-wrap id="nutrients-09-00325-t006" orientation="portrait" position="float"><object-id pub-id-type="pii">nutrients-09-00325-t006_Table 6</object-id><label>Table 6</label><caption><p>Comparisons of fatty acid levels in plasma phospholipids after 12 weeks of intervention.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="top" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Fatty Acid</th><th align="center" valign="top" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Group I</th><th align="center" valign="top" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Group II</th><th align="center" valign="top" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Group III</th></tr></thead><tbody><tr><td align="center" valign="top" rowspan="1" colspan="1">16:0</td><td align="center" valign="top" rowspan="1" colspan="1">29.47 ± 2.31</td><td align="center" valign="top" rowspan="1" colspan="1">28.85 ± 2.62</td><td align="center" valign="top" rowspan="1" colspan="1">29.67 ± 3.88</td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1">16:1 <italic>n</italic>-7</td><td align="center" valign="top" rowspan="1" colspan="1">0.53 ± 0.23</td><td align="center" valign="top" rowspan="1" colspan="1">0.58 ± 0.26</td><td align="center" valign="top" rowspan="1" colspan="1">0.57 ± 0.12</td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1">18:0</td><td align="center" valign="top" rowspan="1" colspan="1">16.77 ± 2.53</td><td align="center" valign="top" rowspan="1" colspan="1">16.34 ± 1.41</td><td align="center" valign="top" rowspan="1" colspan="1">16.55 ± 1.82</td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1">18:1 <italic>n</italic>-9</td><td align="center" valign="top" rowspan="1" colspan="1">8.05 ± 1.05</td><td align="center" valign="top" rowspan="1" colspan="1"> 8.44 ± 0.93</td><td align="center" valign="top" rowspan="1" colspan="1">8.35 ± 1.39</td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1">18:1 <italic>n</italic>-7</td><td align="center" valign="top" rowspan="1" colspan="1">1.58 ± 0.25</td><td align="center" valign="top" rowspan="1" colspan="1">1.63 ± 0.23</td><td align="center" valign="top" rowspan="1" colspan="1">1.68 ± 0.30</td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1">18:2 <italic>n</italic>-6LA</td><td align="center" valign="top" rowspan="1" colspan="1">26.03 ± 2.91</td><td align="center" valign="top" rowspan="1" colspan="1">26.30 ± 2.41</td><td align="center" valign="top" rowspan="1" colspan="1">27.49 ± 3.96</td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1">18:3 <italic>n</italic>-3ALA</td><td align="center" valign="top" rowspan="1" colspan="1">0.21 ± 0.13</td><td align="center" valign="top" rowspan="1" colspan="1">0.18 ± 0.15</td><td align="center" valign="top" rowspan="1" colspan="1">0.19 ± 0.23</td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1">18:3 <italic>n</italic>-6GLA</td><td align="center" valign="top" rowspan="1" colspan="1">0.00 ± 0.00</td><td align="center" valign="top" rowspan="1" colspan="1">0.13 ± 0.11 ***###</td><td align="center" valign="top" rowspan="1" colspan="1">0.00 ± 0.00</td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1">20:3 <italic>n</italic>-6DGLA</td><td align="center" valign="top" rowspan="1" colspan="1">2.46 ± 0.94</td><td align="center" valign="top" rowspan="1" colspan="1">2.69 ± 0.63</td><td align="center" valign="top" rowspan="1" colspan="1">2.67 ± 0.77</td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1">20:4 <italic>n</italic>-6AA</td><td align="center" valign="top" rowspan="1" colspan="1">10.22 ± 1.81</td><td align="center" valign="top" rowspan="1" colspan="1">11.29 ± 2.14 *#</td><td align="center" valign="top" rowspan="1" colspan="1">9.60 ± 2.90</td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1">20:5 <italic>n</italic>-3EPA</td><td align="center" valign="top" rowspan="1" colspan="1">1.01 ± 1.02 **</td><td align="center" valign="top" rowspan="1" colspan="1">0.49 ± 0.23 *#</td><td align="center" valign="top" rowspan="1" colspan="1">0.34 ± 0.16</td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1">22:4 <italic>n</italic>-6</td><td align="center" valign="top" rowspan="1" colspan="1">0.32 ± 0.13</td><td align="center" valign="top" rowspan="1" colspan="1">0.34 ± 0.13</td><td align="center" valign="top" rowspan="1" colspan="1">0.29 ± 0.13</td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1">22:5 <italic>n</italic>-3DPA</td><td align="center" valign="top" rowspan="1" colspan="1">0.58 ± 0.30</td><td align="center" valign="top" rowspan="1" colspan="1">0.45 ± 0.16</td><td align="center" valign="top" rowspan="1" colspan="1">0.56 ± 0.69</td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1">22:6 <italic>n</italic>-3DHA</td><td align="center" valign="top" rowspan="1" colspan="1">2.74 ± 1.08 *</td><td align="center" valign="top" rowspan="1" colspan="1">2.22 ± 0.74 *</td><td align="center" valign="top" rowspan="1" colspan="1">1.83 ± 0.72</td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1"><italic>n</italic>-3</td><td align="center" valign="top" rowspan="1" colspan="1">4.55 ± 2.26 **</td><td align="center" valign="top" rowspan="1" colspan="1">3.33 ± 1.00 *</td><td align="center" valign="top" rowspan="1" colspan="1">2.66 ± 0.81</td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1"><italic>n</italic>-6</td><td align="center" valign="top" rowspan="1" colspan="1">39.05 ± 3.22</td><td align="center" valign="top" rowspan="1" colspan="1">40.75 ± 2.86</td><td align="center" valign="top" rowspan="1" colspan="1">40.03 ± 2.71</td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1"><italic>n</italic>-6/<italic>n</italic>-3</td><td align="center" valign="top" rowspan="1" colspan="1">10.62 ± 5.07 **</td><td align="center" valign="top" rowspan="1" colspan="1">13.50 ± 4.81 *</td><td align="center" valign="top" rowspan="1" colspan="1">16.24 ± 3.14</td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1">SFA</td><td align="center" valign="top" rowspan="1" colspan="1">46.24 ± 3.97</td><td align="center" valign="top" rowspan="1" colspan="1">45.19 ± 2.80</td><td align="center" valign="top" rowspan="1" colspan="1">46.26 ± 3.67</td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1">MUFA</td><td align="center" valign="top" rowspan="1" colspan="1">10.16 ± 1.34</td><td align="center" valign="top" rowspan="1" colspan="1">10.67 ± 1.12</td><td align="center" valign="top" rowspan="1" colspan="1">10.61 ± 1.74</td></tr><tr><td align="center" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">PUFA</td><td align="center" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">43.13 ± 3.17</td><td align="center" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">44.07 ± 2.96</td><td align="center" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">43.60 ± 4.22</td></tr></tbody></table><table-wrap-foot><fn><p>* Significantly different from the group III (<italic>p</italic> ≤ 0.05); ** (<italic>p</italic> ≤ 0.01); *** (<italic>p</italic> ≤ 0.001). # Significantly different from the group I # (<italic>p</italic> ≤ 0.05); ### (<italic>p</italic> ≤ 0.001). Assessed by one-way ANOVA followed by the Tukey post hoc test. Data are expressed as the mean ± SD; Abbreviations as in <xref ref-type="table" rid="nutrients-09-00325-t003">Table 3</xref>.</p></fn></table-wrap-foot></table-wrap></floats-group></article>